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ABSTRACT 
 
Homeostasis of eukaryotic cells is largely dependent on dynamic 
compartmentalization of the endo-membrane system. The membrane 
trafficking linking different organelles is essential to maintain a proper 
composition of various compartments as well as to transport various 
molecules to appropriate compartments. Thus, the molecular machinery 
regulating properly the intracellular membrane trafficking has a key role in the 
maintenance of organelle functionality and cell viability. It is not surprising that 
alterations in membrane trafficking can result in different pathologies. Respect 
to other cell types nervous system is more sensitive to disturbances of the 
membrane trafficking. Hence, to understand how alterations of the 
intracellular trafficking could lead to neurodegeneration, we focused our 
attention on two nervous system disorders, Charcot-Marie Tooth disease 4J 
(CMT4J) and Parkinson disease (PD), both caused by mutations of an inositol 
phospahatase (Fig4 and Synj1, respectively). Together with specific kinases, 
the activity of phospahatases control, the levels of phosphoinosities (PI), a 
class of phospholipids that even more is emerging to be involved in the 
regulation of membrane trafficking.  
Numerous findings highlighted that the levels of PI might be finely regulated, 
in time and in the space, and are critical for membrane homeostasis. 
Specifically PI metabolism seems critical for nervous system functions.  
Aim of my PhD project was to explore the role of Fig4 and Synj1 in the 
membrane trafficking and neurodegenaration in CMT4J and Parkinson 
neuropathies. 
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INTRODUCTION 
Homeostasis of eukaryotic cells is largely dependent on dynamic 
compartmentalization of the endo-membrane system. Intracellular 
compartments are designed so that they can exchange materials and undergo 
dramatic morphological changes in order to meet the demands of metabolism, 
growth, and environment. Hence, membrane trafficking linking different 
organelles is essential to maintain a proper composition of various 
compartments as well as to transport various molecules to appropriate 
compartments. Two pathways mainly achieve this: the biosynthetic secretion 
and the endocytic route. The anterograde flow is counterbalanced by 
retrograde transport, which is essential for the maintenance of organelle 
homeostasis and re-use of components of the trafficking machineries. The 
out-going and in-coming pathways communicate through bidirectional 
transport between the Golgi complex and endosomes. Strikingly, the 
endosomal system, which is a crossroads of distinct intracellular pathways, 
has emerged and is still emerging more as key player in the sorting of 
molecules throughout the cell. 
Thus, the molecular machinery regulating properly the intracellular membrane 
trafficking has a key role in the maintenance of organelle functionality and cell 
viability. It is not surprising that alterations in membrane trafficking can result 
in different pathologies. Indeed, genetic defects of cargo proteins or 
components of the trafficking machinery (responsible for cargo sorting, 
tethering, docking and fusion of vesicles at the target membrane as for their 
motility) leading to abnormal trafficking have been found involved in a large 
number of different human diseases. Interestingly, respect to other cell types 
nervous system is more sensitive to disturbances of the membrane trafficking 
as supported by the fact that various neurodegenerative and neurological 
disorders are caused by mutations or dysfunction of trafficking machinery 
components. 
Main goal of my laboratory is to unravel the role of membrane trafficking in the 
proper functions of nervous system as to understand how alterations of the 
intracellular trafficking could lead to neurodegeneration. In particular, during 
my PhD programme we focused our attention on two nervous system 
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disorders, Charcot-Marie Tooth disease 4J (CMT4J) and Parkinson disease 
(PD), both caused by mutations of a lipid phosphatase. 
 
CHARCOT MARIE TOOTH (CMT) 
Charcot Marie Tooth disease (CMT) is an inherited group of peripheral 
neuropathies bearing the name of the three doctors (Jean Charcot, Pierre 
Marie and Howar Henry Tooth) who described the disease for the first time in 
1886. CMT, also referred to as hereditary motor and sensory neuropathy 
(HMSN), is the most common inherited degenerative disorder of the 
peripheral nervous system with a prevalence of about 1 in 2500 persons 
(Saporta et al, 2011; Patzko and Shy, 2011; Reilly et al, 2011; Tazir et al, 
2013).  
Clinically, CMT diseases are characterized by distal muscle weakness and 
atrophy, sensory loss affecting the feet and hands, hyporeflexia (Saporta et al, 
2011; Patzko and Shy, 2011; Reilly et al, 2011). Additionally, deep tendon 
reflexes are often depressed and skeletal anomalies such as hammertoe 
deformity and pes cavus are present (Saporta et al, 2011; Patzko and Shy, 
2011; Reilly et al, 2011). There can be a wide age of onset and severity range 
in CMT both inter- as well as intra-familial (Patzko and Shy, 2011; Reilly et al, 
2011; Siskind et al, 2013). Most patients begin to show symptoms within the 
first two decades of life, while others develop few if any symptoms until 
adulthood. However, many patients are affected by severe forms developing 
in infancy or early childhood, which were also classified as congenital 
hypomyelinating neuropathy and Dejerine-Sottas neuropathy (Reilly et al, 
2011; Saporta et al, 2011). Life span is not shortened, though quality of life 
may be decreased since patients usually remain ambulatory throughout their 
life and often need ankle-foot orthotics (Arnold et al, 2005). 
The historical classification based on nerve conduction velocity (NCV) of 
median or ulnar nerve (Harding and Thomas, 1980) is fundamental and 
remains the cornerstone of modern diagnosis. By this electrophysiological 
parameter, CMT are classified in two main types: CMT1 (also defined 
demyelinating) characterized by NCV <38 m/s; CMT2 (also defined axonal) 
with a NCV> 38 m/s (Saporta et al, 2011; Reilly et al, 2011; Tazir et al, 2013). 
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Intermediate forms with intermediate values of NCV between 35 and 45 m /s 
were also identified (Saporta et al, 2011; Reilly et al, 2011; Tazir et al, 2013). 
The current classification is based on the combination of the 
electrophysiological parameter, inheritance pattern and causative genes (Fig. 
1). While intermediate forms of CMT are mainly dominant (AD), CMT1 and 
CMT2 are inherited both as an autosomal dominant trait as well as autosomal 
recessive (AR) and X-linked trait (Reilly et al, 2011; Siskind et al; 2013). The 
prevalence varies in different populations. In Western Europe, United States 
and Japan the dominant forms are by far the most frequent, whereas in the 
Mediterranean basin and Middle East communities, with high percentage of 
consanguineous marriages, autosomal recessive forms account for 30-50% of 
all CMT cases (Reilly et al, 2011; Siskind et al; 2013).  
So far, there are at least 40 genes known to cause CMT when mutated (Fig. 
1) and more than 44 distinct loci have been identified (Shy et al, 2005; Siskind 
et al, 2013). Nonetheless, more than 70% of patients with CMT in Western 
countries have genetic abnormalities associated with essentially four genes: 
PMP22, MPZ, MFN2 and GJB1 (Saporta et al, 2011). While most of the 
known CMT gens are strictly implicated either in axonal or demyelinating 
form, some others like GDPAP1, NEFL and MPZ may be mutated in both 
forms. Furthermore, while certain genes mutations are mainly of dominant 
inheritance and others recessive, some of them such as EGR2, PMP22, MPZ, 
NEFL, MFN2, GAPDP1 and HSPB1 mutations may be of both inheritance 
traits.  
 
CHARCOT MARIE TOOTH 4J (CMT4J) 
Charcot-Marie-Tooth 4J (CMT4J) is a rare recessive demyelinating form of 
CMT. The designation of CMT4 (instead of AR-CMT1) is applied to all 
autosomal recessive forms of demyelinating CMT (Fig. 2). Ten sub-types 
(from the CMT4A CMT4J; Fig 2) corresponding to the ten mutated genes 
have been identified to date (Tazir et al, 2013). 
CMT4J is characterized by severe motor dysfunction with rapid clinical 
progression that results in weakness, often asymmetric, of proximal and distal 
muscles. Initially, the CMT4J phenotype was described as a severe early 
onset CMT (Chow et al., 2007), but further studies showed that the CMT4J 
Fig. 1: Genetic classification of Charcot-Marie-Tooth (CMT). CMT are classified in
CMT1, CMT2 and intermediate CMT on the basis of the nerve conduction velocity
(NCV). CMT can be inherited as dominant, recessive and X-linked trait (from Reilly et
al. 2011).
Fig 2: Classification of autosomal recessive CMT4. The designation of CMT4
(instead of AR-CMT1) is applied to all autosomal recessive forms of demyelinating
CMT. Ten sub-types (from the CMT4A to CMT4J) corresponding to the ten mutated
genes have been identified to date.
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was characterized by a highly variable onset, from early childhood through to 
the sixth decade, and severity (Tazir et al, 2013). Even, early loss of 
ambulation has been found in some patients. Moreover, it has been observed 
that, beyond the motor neurons, sensory neurons are also affected (Chow et 
al., 2007; Zhang et al., 2008). In fact, CMT4J patients exhibit, albeit slight, 
sensory abnormalities such as reducing the sensitivity of the distal limbs and 
decreased tendon reflex (Saporta et al, 2011; Tazir et al, 2013). On 
neurological examination, dysfunction of the cranial nerves is uncommon and 
these patients usually display normal cognitive function. Consistently, no 
abnormalities of the central nervous system have been observed in patients 
with CMT4J (Nicholson et al. 2011; Zhang et al. 2008). Mutations in the lipid 
phosphatase Fig4 causes CMT4J (Chow et al, 2007). Affected individuals are 
compound heterozygotes carrying one unique null allele of FIG4 in 
combination with the missense allele FIG4-I41T (more frequent) or FIG4-L17P 
(Chow et al. 2007; Nicholson et al. 2011).  
The recessive mutations appear to result in a loss of function of Fig4. 
Homozygous “pale tremor” (plt) mice with a spontaneous mutation (through a 
transposon insertion) that eliminates the expression of Fig4 exhibit extensive 
and progressive neurodegeneration in the brain and peripheral ganglia (Chow 
et al, 2007; see also box1).  In particular, extensive loss of neurons from 
sensory and autonomic ganglia is evident during the neonatal period. 
Peripheral nerves are also affected consistently with the observed reduction 
of nerve conduction velocities and CMAP (compound muscle action 
potentials) amplitude (Chow et al, 2007).  
 
Histological phenotype 
Sural nerve biopsies of CMT4J patients show extensive loss of large-diameter 
myelinated fibers and onion bulb lameallae surrounding some remaining 
demyelinating fibers (Fig. 3) (Zhang et al., 2008; Nicholson et al, 2011). There 
is relative sparing of moderate to small diameter fibers, which range from 
thinly myelinated to absent myelin. These features are also seen in sciatic 
nerve of plt mice (Chow et al, 2007). 
Hence, the defects in myelin sheath formation could imply the involvement of 
glial cells in the pathogenesis of disease. This is supported by recent findings 
Enlarged vacuoles Enlarged vacuoles
Reduced PI(3,5)P2 Reduced PI(3,5)P2
Slowed nerve conduction
velocities
Slowed nerve conduction
velocities
Peripheral neuronopathy Peripheral neuronopathy
Motor system defects Motor system defects
CNS neuronal degeneration Axonal loss
Diluited pigmentation
Cell loss in spleen
Survive 4-6 weeks Little effects on lifespan
Box 1: The ‘pale tremor mouse’ as model of CMT4J.
The pale tremor mouse recapitulates CMT4J phenotype therefore is a
good model to study this desease. Mice exhibit severe tremors starting
early in life, abnormal gait, motor dysfunction and reduced NCV. At
postnatal day three (P3), affected homozygotes have reduced size.
Intentional tremor develops during the second week after birth, and
abnormal limb postures are evident by the third week. Furthermore the
pale tremor mice have impaired motor coordination, muscle weakness
and ‘swimming’ gait. There is a progressive loss of mobility, reduction in
body weight and juvenile lethality. Within the brain, neuropathy is
observed as early as P7 in the thalamus, pons, medulla, cortical layers V
and VI, and the olfactory bulb. Many areas of them are involved in motor
control, emphasizing similarity to CMT. Differently from humans, mice
show diluted pigmentation suggesting that the loss of Fig4 affects
melanosome functions. Furthermore at cellular level large vacuoles are
observed in the trigeminal ganglia by post-natal day 1 (P1), the dorsal
root ganglia by P7, and the spinal motor neurons by 6 weeks of age.
Fig. 3: Sural nerve biopsy of a patient with CMT4J. Anomalies in myelinated fibers
are detected in a sural biopsy of CMT4J patient. (A) Cross section of a sural nerve
fascicle with extensive loss of large myelinated fibers. There is relative sparing of
moderate to small diameter fibers, which range from thinly myelinated (arrowheads) to
absent myelin (arrows). (B) Electron microscopy demonstrating one naked axon with
myelin breakdown products (arrowhead) and one thinly myelinated axon with
surrounding onion bulb remnants and no clear Schwann cell processes (arrow). (C)
Thinly myelinated axon with multiple thin myelin bands within the surrounding onion
bulb (arrow). Also visible, a demyelinated axon (arrowhead) and a thinly myelinated
axon (curving arrow). (D) Electron microscopy demonstrating a minimally myelinated
axon with myelin breakdown products. Arrows indicate the cell remnants of a Schwann
cell (from Nicholson et al. 2011).
Fig. 4 : Vacuolation in FIG4-deficient human fibroblasts. Fibroblasts of normal
(left) and CMT4J patient (right). Control fibroblasts contains occasional vacuoles, while
there are excessive vacuoles in patients fibroblasts (arrows) (from Zangh et al. 2001).
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showing that mice with conditional inactivation of Fig4 in Schwann cells 
display demyelination (Vaccari et al, 2014). 
 
Cellular phenotype 
At the cellular level, plt mice display: i) enlarged vacuoles with watery 
appearance immunoreactive for the late endosomes/lysosomes protein lamp2 
in sensory neurons (Chow et al. 2007; Ferguson et al. 2009); ii) enlarged 
Lamp1/2 positive endo-lysosomes filled with electron dense material (Chow et 
al, 2007; Katona et al, 2011) in spinal motor/cortical neurons and glia. Lamp-2 
reactive vacuoles accumulation is also observed in fibroblasts from patients 
with CMT4J (Zhang et al. 2008) (Fig. 4).   
Thus, it appears that the deficiency of Fig4 leads to wide expansion and, 
probably, to dysfunction of the late endosome/lysosome compartments. 
Moreover, the observed differences of the cellular phenotype in the different 
types of neurons suggest that Fig4 might have different roles in the diverse 
cell types possibly by controlling specific cell pathways.  
Furthermore, elevated levels of LC3-II and p62 have been detected in the 
brains and spinal cord of plt mice (Ferguson et al, 2009). Interestingly, this 
accumulation was not observed in liver or other non-neural tissues, 
suggesting that a defect of autophagy pathway could contribute to 
neurodegeneration phenotype. Moreover, in the brain homogenates there is 
no change in cytoplasmic LC3-I and in the levels of protein involved in the 
initiation of autophagy as Beclin-1 and mTOR (Ferguson et al, 2009), 
suggesting that a block in completion of autophagy rather than its up-
regulation could be the defect of Fig4-/- mice.   
 
FIG4 
In humans FIG4 gene is located on chromosome 6 (from base pair 
109,691,221 to base pair 109,825,43). It encodes a lipid phosphatase of 103 
kDa comprised of 907 amino acids, the Fig4 protein, also known as SAC 
domain-containing protein 3 (Sac3) (Chow et al, 2007).  
Fig4 belongs to the family of enzymes (from lower to higher eukaryotes) 
containing a conserved phosphoinositide (PI) phospahatase module termed 
Sac (suppressor of actin) domain (Hughes et al, 2000). Fig4 was originally 
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identified in a screen for genes induced by mating pheromone in 
Saccharomyces cerevisiae (Erdman et al, 1988). The mammal protein is 
closely related to the yeast one with overall amino acid sequence identity of 
35% and similarity of 66% (Chow et al, 2007). 
The Sac domain comprises about 500 amino acids and contains seven highly 
conserved motifs including the CX5R(T/S) catalytic motif, which is essential 
for catalytic activity (Hughes et al, 2000).  Like in yeasts, also in humans there 
are five Sac phosphatase domain containing proteins, which appear to fall into 
two subfamilies (Fig. 5). Members of the first subfamily, including the trans-
membrane protein Sac1, cytosolic proteins Sac2/INPP5f and Sac3/Fig4, have 
an N-terminal Sac phosphatase and no other recognizable structural domains. 
The second subfamily comprises two synaptojanin homologues, which have a 
PI 5-phosphatase domain immediately after the N-terminal Sac phosphatase 
module (Hughes ate al, 2000). Each Sac phosphatase prefers a specific sub-
group of PIs as substrates, although how the substrate specificity is 
determined in still not well clear. Specifically, Fig4 removes the 5-phosphate 
from the phosphoinositide PI(3,5)P2 to generate PI(3)P both in vitro and in 
vivo (Rudge et al, 2004; Duex et al, 2006). 
Consistently with public expressed-sequence-tag and microarray databases, 
RT-PCR of tissues from wild type mice showed widespread expression of 
Fig4 (Chow et al, 2007). Moreover, transcript appears distributed throughout 
the brain as revealed by in situ hybridization (Chow et al, 2007).  
 
Structure and enzymatic activity 
Structural studies of Fig4/SAC3 have not yet been performed, but important 
information has been inferred through the crystal structure of the founding 
member of this family, the Sac1p, which is the only crystal structure solved in 
this family to this day (Manford et al, 2010). The Sac domain of yeast Sac1p 
comprises two closely packed sub-domains (Fig. 6): an N-terminal sub-
domain  (SacN domain; residues 1-182) and a C-terminal domain of about 
320 residues in which is present the catalytic site CX5R(T/S) (Manford et al, 
2010). The SacN domain comprises three layers of β-sheets and one long 
and three short α-helixes (Fig. 6). The SacN domain is closely opposed to the 
catalytic domain, but it takes some contacts through its third layer (Manford et 
Fig. 6: Overall crystal structure of Sac1. (A) Ribbon diagram of the Sac PI
phosphatase. The SacN domain is coloured blue and the catalytic domain yellow. The
secondary structure elements (strands β1–β18 and helices α1–α9) are labelled. The
catalytic CX5R(T/S) motif (P-loop) is coloured red and labelled. Five protruding loops
(L1–L5) surrounding the catalytic site are coloured green. (B) a 90º rotated view of (A).
(C) Schematic diagram of the secondary structure topologies of Sac1 (from Manford et
al. 2010).
Fig. 5: Domain structures of the members of the Sac phosphoinositide
phosphatase family. Both in human and yeast, there are five proteins containing the
Sac phosphatase module (TM transmembrane module, RBD RNA binding module)
(from Manford et al. 2010).
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al, 2010). The function of this domain is still unknown, but it may control the 
enzymatic function through the interactions with other unknown factors. The 
catalytic domain consists of a nine-stranded and partially split β-sheet that is 
flanked by five α-helixes with two on one side and three on the other. The 
catalytic site (residues 392-399) is constituted by a conserved cysteine (Cys) 
followed by 5 amino acids and arginine (Arg) forming a conserved loop 
(termed P-loops; in red in Fig. 6). Finally, five protruding loops surrounding the 
catalytic site (Manford et al, 2010).  
Moreover, the Sac domain is an electrostatic bipolar protein with one surface 
negatively charged and the opposite surface enriched with positive charges 
(Manford et al, 2010). The positive charged face is likely to interfaces with the 
lipid bilayer interacting with the negative charges of the phospholipids. 
Consistently, the catalytic motif CX5R (T/S) is localized on this positively 
charged surface. 
Through a conserved mechanism in yeast and in mammals, Fig4 formed a 
ternary complex (Fig. 7) with PIKfyve (Fab1 in yeast) and the ArPIKfyve 
adaptor protein (Vac14 in yeast), which regulates both the kinase and 
phosphatase activities (Jin et al, 2008; Ho et al, 2011). Yet, it is not 
completely clear the dynamics through which this complex is formed and then 
performs its function, nor how it is regulated. Various studies suggest that 
Fig4 could bind Vac14/ArPIKfyve before to bind efficiently the kinase 
Fab1/PIKfyve (Botelho et al, 2008; Ikonomov et al, 2009; Sbrissa et al., 2007). 
This complex is responsible for the acute regulation of subcellular levels of 
PI(3,5)P2 (Botelho et al, 2008; Jin et al, 2008; Sbrissa et al, 2008). Similarly to 
the deficit of Fig4, the loss of Fab1, which is lethal in some eukariotes such as 
C. elegans and Drosophila, induces the formation of an enlarged, swollen 
vacuole in yeast cells (Efe et al, 2005) or the loss of ArPIKfyve in mice leads 
to massive neurodegeneration with accumulation of lamp2-positive vacuoles 
(Zhang et al, 2007). All together these findings indicate that the levels of 
PI(3,5)P2 might be finely regulated and are critical for membrane homeostasis 
and specifically survival of neural cells. 
How the function of Fig4 is impaired in the disease mutants is still not 
understood since both pathological mutations mapped outside of catalytic site 
(Fig. 7, 8). The pathological mutant Fig4I41T (presumably also Fig4L17P) 
Fig. 7: The ternary complex containing Fig4, PIKfyve (FAB1) and ArPIKfyve
(VAC14) regulates the overall concentration of PI(3,5)2P. Predicted orientation of
Fig4 in complex is shown. The image shows the N-terminal domain (blue) and the
catalytic domain (yellow) containing the active site (green). The I41T mutation of Fig4
is represented in red (from Lenk et al. 2011).
Fig. 8: I41T mutation is localized away from the catalytic site. The picture shows
the localization of I41T predicted on the basis of crystal structure of yeast Sac1p.
Together with residues D48G and D53Y (found mutated in ALS) I41T is clustered in a
surface area on the top of the SacN domain. R388G and I411V are located in the
catalytic domain and create a non-functional protein.
/ARPIKFYVE
/ PIKFYVE
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maintains its hydrolysing activity, but it appears to be unstable as 
consequence of the impairment of its interaction with ArPIKfyve, although 
there are conflicting data (Ikonomov et al, 2010; Lenk et al, 2011). ArPIKfyve 
seems to regulate the abundance of Fig4 by attenuating proteasome-
dependent degradation (Ikonomov et al, 2010). Instead, through a mechanism 
still unclear ArPIKfyve would be unable to stabilize mutant protein, although it 
associates with Fig4I41T in similar manner to wild-type protein (Ikonomov et 
al, 2010). 
Hence, these findings do not adequately explain the pathogenesis of CMT4J. 
Consistently, the overexpression of the mutant is unable to rescue all 
degenerative defects of plt mice (Lenk et al, 2011). This is also different to 
what occurs in yeast where Fig4 carrying a corresponding I59T mutation was 
able to produce normal levels of PI(3,5)P2 and is sufficient to correct the 
vacuolar enlargement phenotype when this mutant was expressed in Fig4-/- 
cells (Chow et al. 2007). Although many similarities between yeast and 
mammals, these findings suggest that Fig4 can be differently regulate in these 
organisms or can be implicated in diverse cellular functions and this could be 
related to CMT4J pathogenesis. 
Another hypothesis is that Fig4 could be essential for the function of the 
ternary complex as scaffold protein, thus implying that Fig4 could be involved 
both in the degradation (through its phosphatase function) and synthesis of 
PI(3,5)P2. Hence, in the absence of Fig4 ArPIKfyve/Vac14 fails to exert its 
activity or, alternatively, Fig4 may be a direct activator of PIKfyve. This is in 
agreement with the fact that Fig4-deficient yeast cells and mice do not have 
higher PI(3,5)P2, but instead, have lower basal levels (Chow et al, 2007; Duex 
et al, 2006). Moreover, in yeast the deletion of FIG4 impairs the localization of 
VAC14 and PIKfyve to the vacuole surface (Jin et al. 2008; Rudge et al. 
2004).  However, there are conflicting data in mammals:  Fig4 is destabilized 
in mutant mice lacking VAC14, while VAC14 and PIKfyve are stable in mice 
lacking Fig4 (Lenk et al. 2011). 
By computationally modelling of the structure of Sac domain based on the 
crystal structure of yeast Sac1p, the I41T localizes at c-terminal end of β3 in 
the SacN domain (Fig. 8) and is about 40 Å to the catalytic site confirming that 
mutation does not affect the catalytic activity of Fig4 (Manford et al, 2010). 
! 17!
The hydrophobic side chain of this isoleucine is buried in a hydrophobic core 
between the first two layers of β-sheets of the SacN domain (Fig. 6, 8). The 
mutation may affect the local folding or the stability of the protein because 
together with residues D48 and D53 the I41 residue is surface exposed and 
located in flexible loop regions (Fig. 8; Manford et al, 2010). In addition, this 
surface area of SacN domain may be involved in protein-protein interactions 
and therefore the I41T mutation could affect them. 
 
 
!
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PARKINSON'S DISEASE 
Parkinson disease (PD) is the second most common neurodegenerative 
disorder with a prevalence of about 1% in people over 60 years of age 
to about 4% in people over the age of 85 (De Lau et al. 2006). It was first 
described in the essay entitled “n Essay of the Shaking Palsy” by James 
Parkinson in 1817.  
Clinically, PD is characterized by a wide spectrum of symptomatology 
including motor symptoms such as resting tremor, bradykinesia, rigidity, 
postural instability, stooped posture and freezing (Fig. 9), as well as non-
motor symptoms including cognitive and behavioural symptoms, sleep 
disorders, autonomic dysfunction, olfactory and other sensory deficits and 
fatigue (Polymeropoulos et al.1997; Hely et al., 2008). 
The neuropathological hallmarks are characterized by progressive and 
profound loss of neuromelanin containing dopaminergic neurons in the 
substantia nigra pars compacta (SNpc) with presence of eosinophillic, 
intracytoplasmic, proteinaceous inclusions (mainly enriched of α-synuclein) 
termed as Lewy bodies (LB; Fig. 10) and dystrophic Lewy neurites in surviving 
neurons (MacPhee & Stewart, 2001; Thomas and Beal 2007). At the time of 
death, even middle affected PD patients have lost about 60% of their 
dopaminergic neurons (Zigmond and Burke, 2002; Jankovic et al, 2013). The 
depletion of striatal dopamine as a result of SNpc dopaminergic neuronal loss 
leads to an impaired nigro-striatal system that otherwise allows an individual 
to execute proper, coordinated movements. Indeed, dopamine is important for 
tuning down the cortical excitation of striatal neurons and therefore its loss 
may lead to an increase of corticostriatal glutamatergic transmission that in 
turn overactives striatal γ-aminobutyric acid (GABA) output (Robertson et al. 
1990). 
Moreover, although neuronal loss in substantia nigra is pronounced there is 
widespread neurodegeneration in the central nervous system (Thomas and 
Beal 2007).  
While the neuropathological damage is clear and widely described, the PD 
aetiology remains currently unknown. Two forms of Parkinson’s disease are 
recognized (Fig. 11): a familial or early-onset Parkinson’s disease (<10% of all 
Fig. 9: Classic symptoms of late-stage Parkinson disease. Patients presents a
stooped and rigid posture, shuffling gait and tremor (After Markey 1986).
Fig. 10: Lewy body in the substantia nigra are detected in brains of Parkinson’s
patients. Immunohistochemistry of brain slice of PD patient.
FORMS OF PARKINSON’S  DISEASE
PD Genetic 10%
PD Idiopathic 90%
Fig. 11: Frequency of different forms of Parkinson’s  disease.
Fig. 12: Gene loci identified for Parkinson’s disease.
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patients) and idiopathic or late-onset Parkinson’s disease (>85% of all cases) 
that does not appear to exhibit heritability. Notably, the clinical manifestations 
and neuropathology of familial parkinsonism can often be quite 
indistinguishable from sporadic cases, which fuelled the widely held 
assumption that the two forms of PD are likely to have shared pathogenic 
mechanisms. 
Overall, the pathology of Parkinson’s disease is complex and is most likely a 
consequence of a combination of genetic and environmental factors, which 
may induce a common pathogenic cascade of molecular events (Maguire-
Zeiss and Federoff, 2003; Miller and Federoff 2005; Kalinderi et al, 2016). The 
molecular pathways leading to this pathological picture are still obscure. The 
discovery of several monogenic forms of PD substantially increased our 
knowledge of the neuodegeneration mechanisms in PD (Bonifati el al, 2007; 
Gasser et al; 2007 Dauer and Przedborsky, 2003; Lesage et al, 2009). For 
example abnormal protein processing, oxidative stress, mitochondrial 
dysfunction seems to be leading factors involved in the pathogenesis of PD 
(Gupta et al 2008; Greenamyre and Hastings, 2004). However, two decades 
after the detection of the first mutation associated with PD, the molecular 
basis of this neurodegenerative disease remains incompletely understood. 
Moreover, the precise relationship of familial linked genes to the sporadic 
illness is currently uncertain.  
 
 
Epidemiology 
Until the 1990s Parkinson's disease was the fourth most common 
neurodegenerative disease (Gray & Hildebrand, 2000), currently is the second 
in the world after Alzheimer's disease (Collins et al 2010). It is not possible to 
establish with certainty the age of disease development since mostly several 
years pass between the onset of symptoms and the diagnosis. Considering 
the total population, the prevalence is 1 in 100000, but the incidence 
increases to about 200 after 50 years, and nearly 1000 cases in the oldest 
age group (over 70 or 80 years) indicating that risk of PD increasing with 
advancing age (Korell and Tanner, 2013). Although less frequent, there are 
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also cases diagnosed earlier (around 40 years or below) as well as rare forms 
of juvenile parkinsonism (age onset around 20-25 years). 
Gender-specific differences have been observed in PD incidence and 
prevalence studies (Korell and Tanner, 2013). However, there is variability 
across studies. A preponderance of PD among males has been reported, 
while a few studies have reported similar incidence or prevalence for males 
and females. In Japan, PD prevalence is higher in women, but it could reflect 
longer survival among females in Japan and differential access to medical 
service. In sharp contrast, the incidence of PD among men was approximately 
twofold higher than among women in the Northern California and Italian 
population (Korell and Tanner, 2013). If there are truly gender differences in 
PD across populations, this could be due to differential exposure to risk 
factors (such as occupational exposure to toxicants) in men and women.   
Parkinson's disease is present in all countries with lower incidence in China 
and in Africa and seems affect all races (Korell and Tanner, 2013). Some 
studies showed a lower prevalence among Black as compared to Whites. A 
recent study investigating multi-ethnic population found that incidence rates 
were highest among Hispanics followed by non-Hispanic Whites, Asians and 
Blacks (Korell and Tanner, 2013). 
 
 
GENETIC FORMS OF PARKINSON'S  DISEASE AND INHERITANCE  
The majority of PD cases are sporadic probably caused by a combination of 
genetic and environmental risk factors as aforementioned (Fig. 11). 
Approximately 10% of patients have monogenic forms of the disease, 
exhibiting a classical Mendelian type of inheritance (Lesage et al, 2009; 
Bonifati et al, 2013; Kalinderi et al, 2016).  
The initial observations of positive familial histories in 10-20% of patients have 
shown that genetic factors might be involved in the pathogenesis of the 
disease. A lot of genetic association studies had later on implicated a number 
of genetic variants in the disease pathogenesis/protection. Then the major 
progress has been made with the advent of genome-wide association studies 
(GWAS) and the implementation of new technologies, like next generation 
sequencing (NGS) and exome sequencing.  
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Many chromosomal loci, termed PARK to denote their putative link to PD and 
numbered in chronological order, have been identified (Fig.  12). Nowadays, 
only six of these specific regions contain genes with mutations that 
conclusively cause monogenic typical PD (Singleton et al., 2013; Bonifati et 
al, 2013; Kalinderi et al, 2016). Both dominantly or recessively inherited 
mutations have been found (Bonifati et al, 2013; Kalinderi et al, 2016). 
 
Autosomal dominant forms of PD 
 
Mutations in three genes (SNCA, LRRK2, VPS35) are conclusively 
established as a cause of autosomal dominant forms of PD (Bonifati et al, 
2013; Kalinderi et al, 2016). The evidence for a fourth gene, EIFAG1, remains 
inconclusive (Bonifati et al, 2013). Finally, heterozygous mutations in the GBA 
gene are important and strong risk factors for PD and diffuse Lewy-body 
disease (Bonifati et al, 2013). 
 
Alpha-synuclein (SNCA) was the first gene associated with familial PD by 
linkage mapping and then confirmed by the identification of the missense 
mutation A53T in Italian and Greek families (Polymeropoulos et al. 1997).  
Mutations in SNCA are rare and include point mutations and whole-locus 
multiplications (duplications or triplications). Beyond A53T, A30P and E46K 
mutations have been detected so far in single families of German and 
Spanish origin, respectively. The brain pathology is characterized by 
abundant α-synuclein-positive neuronal inclusions (LBs and Lewy neuritis), 
but the associated clinical spectrum is broad, ranging from classical PD to 
more atypical and aggressive phenotypes (including myoclonus, severe 
autonomic dysfunction and dementia in addition to parkinsonism). The 
patients with SNCA duplications display a classic PD phenotype, while the 
more rare cases carrying triplications have more severe phenotype, indicating 
a direct relationship between SNCA gene dosage and disease severity. Other 
point mutations (H50Q and G51D) have been recently identified in a sporadic 
English patient and in two independent families of French and British origin, 
respectively (Bonifati yet al, 2013). Interestingly all point mutations map at the 
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N-terminal of α-synuclein, suggesting that this domain could be critical for 
protein function. 
Alpha-synuclein is an abundant protein in the brain, but to a lesser extent is 
also expressed in the heart, muscles and other tissues. In the brain α-
synuclein was found mainly at the end of the pre-synaptic terminals, where it 
may interact with both phospholipids and proteins. In particular, it has been 
observed that α-synuclein binds to phospholipids via its amino-terminal end, 
while to synaptobrevin-2 via its carboxy-terminal end (Ben Gedalya et al., 
2009; Nemani et al., 2010). Although its function is not yet fully elucidated, 
several studies suggest that α-synuclein, through the N-terminal domain, 
could be implicated in the regulation of synaptic vesicles trafficking and 
membrane fusion. 
Increased expression of SNCA, both in its native or mutated form, or an 
incorrect degradation result in abnormal formation of insoluble aggregates, 
that can be deposited to form Lewy bodies after neuron demise. Misfolding 
and aggregation of the α-synuclein protein into neurotoxic species is at the 
centre of the current pathogenic theories for PD. The more recent discovery 
that α -synuclein aggregates develop in dopaminergic neurons transplanted in 
the brain of PD patients, suggest that misfolded a-synuclein may have prion-
like properties, and could be able to induce a cascade of protein misfolding. 
 
LRRK2 (Leucine-rich repeat kinase 2) mutations are the most common known 
cause of autosomal dominat PD.  The LRRK2 gene encodes a large protein 
with two enzymatic domains (GTPase and kinases) and multiple protein-
protein interaction domains. Seven mutations (Asn1437His, Arg1441Cys, 
Arg1441Gly, Arg1441His, Tyr1699Cys, Gly2019Ser, and Ile2020Thr) were 
considered to cause disease (Zimprich et al. 2004; Berg et al, 2005). 
Mutations of this gene have been found both in family and sporadic forms of 
Parkinson's disease. 
 
VPS35 (Vacuolar protein sorting-associated protein 35) is a component of a 
large multimeric complex, termed the retromer complex, involved in 
retrograde transport of proteins from endosomes to the trans-Golgi network 
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(Bonifacino et al, 2008). In 2011 two groups reported the identification of the 
same missense mutation in VPS35 gene as novel cause of autosomal 
dominant PD (Vilarino-Guell et al, 2011; Zimprich et al, 2011). 
 
Autosomal recessive forms of PD 
To date, eight causative genes have been identified as cause of autosomal 
recessive parkinsonism.  
Homozygous or compound heterozygous mutations in each of the following 
three genes, parkin (PRKN, PARK2), PINK1 (PARK6), and DJ-1 (PARK7) 
cause autosomal recessive forms of early-onset parkinsonism, usually without 
atypical clinical signs (Kitada et al, 1998; Valente et al, 2004; Bonifati et al, 
2003). Mutations of these three geens are identified worldwide, including point 
mutations and large rearrangements leading to deletions or multiplications.  
Mutations in Park2 gene are the most common and have been found both in 
familial forms (accounting up to half familial PD) and in sporadic PD (15% of 
the cases) with onset before 45 years (Lucking et al, 2000; Bonifati et al, 
2013). Parkin is an ubiquitin E3 ligase. The loss-of-function effect of Parkin 
mutations result in inactivation of its E3 ligase function, failure of ubiquitination 
of the targeted proteins and therefore a toxic build-up of proteins that are no 
longer effectively degraded by the parkin dependent ubiqutin/proteosome 
pathway in the degradation system of proteasome (Shimura et al, 2000). 
Hence, it has hypothesized that he formation of these toxic aggregates to 
neurons of the substantia nigra have a crucial role to the pathogenesis of PD 
(Shimura et al, 2000). 
Mutations in the gene PINK1 and DJ-1 are less common (1-2%; Valente et al, 
2004; Bonifati et al, 2005; Ibanez et al, 2006). The PINK1 protein contains a 
kinase domain and is localized to the mitochondria. Recent studies indicate 
that PINK1 and Parkin are functionally linked, with PINK1 acting upstream of 
parkin (Narendra et al, 2010; Koyano et al, 2014). Indeed PINK1 has been 
found to phosphorylate parkin recruiting it onto depolarized mitochondria 
(Koyano et al, 2014). Together, they are important to tag damaged 
mitochondria for degradation by autophagy (Narendra et al., 2010; Koyano et 
al, 2014). 
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Recessive mutations in Park9 (ATP13A2), PARK14 (PLA2G6), PARK15 
(FBXO7) are responsible of atypical forms of parkinsonism with very early 
(juvenile, <30 years) onset and other clinical signs (such as pyramidal, 
dystonic, ocular movement, and cognitive disturbances) in addition to 
parkinsonisms (Di Fonzo et al, 2009; Ramirez et al, 2006; Bonifati et al, 
2013). Park9 encodes a lysosomal membrane transporter, ATP13A2, while 
PARK15 gene encodes two protein isoforms, which are part of larger 
ubiquitin-ligase complex, but have poorly characterized functions.  
Recently, through exome sequencing approach combined with genome wide 
homozygosity mapping mutations in another two genes, DNAJC6 (encoding 
auxilin) and SYNJ1 (encoding synaptojanin 1) were identified as the cause of 
autosomal recessive, juvenile parkinsonism. DNAJC6 mutations have been 
identified first in Palestinian family and later confirmed in a Turkish family 
(Edvardson  et al, 2012; Koroglu et al, 2013).  
In the case of SYNJ1, the same homozygous mutation, Arg258Gln, was 
identified independently in two families of Iranian and Italian (consanguineous 
family from Sicily) origins (Quadri et al. 2013; Krebs et al. 2013). All four 
patients (2 siblings per family) display early onset parkinsonism with 
progressive bradykinesia and early development of tremors and other motor 
symptoms (at the age of 20). Additional clinical signs such as eyelid apraxia, 
generalized seizures, and dementia have been observed in some patients 
(Quadri et al, 2013; Krebs et al, 2013). One year later, the same homozygous 
mutation is found in two siblings of a third pedigree affected by progressive 
early-onset parkinsonism (Olgiati et al, 2014). 
 
 
SYNJ1  
Synaptojanin 1 (Synj1) is a lipid phosphatase belonging to the family of Sac 
domain containing proteins as aforementioned. It was discovered in 1994 as 
145 kDa nerve terminal protein interacting with growth factor receptor-bound 
protein 2 (Grb2) (Mcpherson et al, 1994). Two decades later, Synj1 mutation 
was incriminated for the first time in autosomal recessive early-onset 
Parkinson’s disease with atypical symptoms (Quadri et al, 2013; Krebs et al, 
2013). 
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The SYNJ1 gene is located on chromosome 21q22.11 (Cremona et al. 2000) 
and spans 99.29 kb of genomic DNA. Two isoforms are generated from two 
open reading frames separated by an in-frame stop codon (Ramjaun and 
McPherson, 1996). The first open reading frame encodes a 145-kDa form of 
the protein (1350 amino acids), whereas a 170-kDa isoform appears to be 
composed of both open reading frames (1612 amino acids) (Ramjaun and 
McPherson, 1996). Whereas the 145-kDa isoform is highly enriched in adult 
brain, the 170-kDa isoform is excluded from this tissue (Ramjaun and 
McPherson 1996). Both isoforms harbor multiple functional domains (Fig. 13): 
a Sac domain on their N-terminal (typically of this enzyme family), a 5’-
phosphatase domain in the centre, and a C-terminal proline-rich domain 
(PRD). The 170 kDa isoform contains an additional PRD translated from the 
second ORF (Ramjaun and McPherson, 1996).  
There are two additional SYNJ1 isoforms: isoform c 1295 amino acids and 
isoform d 1526 amino acids, that are of unknown functional relevance. 
Despite isoforms c and d have a shorter N-terminus and a distinct C-terminus 
and are shorter than isoform a, they contain the same functional domains as 
isoforms b and a, respectively. 
Furthermore, there is another form of synaptojanin, synaptojanin 2 (1248 
amino acids), always identified by De Camilli’s group (Nemoto et al, 1997). 
The two synaptojanin forms share 57.2 and 53.8% amino acid identity in their 
Sac and phosphatase domains, respectively, while their carboxyl-terminal 
PRD domain bear little homology. Synj2 has a broader tissue distribution and 
possess inositol 5-phosphatase activity (Nemoto et al, 1997). Protein binding 
assays demonstrated that among the proteins binding the proline-rich region 
only Grb2 binds to synaptojanin 2 (Nemoto et al, 1997). Furthermore, 
subcellular fractionation studies in transfected CHO cells revealed that 
synaptojanin 2 was predominantly associated with the membrane fraction, 
while synaptojanin 1 was mainly localized in the soluble fraction (Nemoto et 
al, 1997), suggesting that PRD domains of Synj1 and 2 are implicated in 
different protein-protein interactions. 
Synj1 is an inositol 5-phosphatase and it converts PI(1,4,5)P3 but not  
PI(1,3,4)P3 to inositol bisphosphate (Mcpherson et al, 1996). In addition it 
dephosphorylates PI(4,5)P2 to PI monophosphate (Mcpherson et al, 1996).  
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Protein domains  
Respect to other inositol phosphatases Synj1 is peculiar because it contains 
two consecutive phosphatase domains, the Sac1 and the 5'-phosphatase 
domains. Specifically, it is composed of three domains (Fig 13): 
1) at the N-terminus the Sac domain, homologous to the yeast Sac1p, 
dephosphorylates predominantly PI monophosphates present in cell 
membranes, including those of the Golgi apparatus and endosomes. 
2)  the central 5'-phosphatase domain dephosphorylates 
phosphatidylinositol bis- or trisphosphates localized in plasma 
membranes to activate downstream pathways (Perera et al, 2006; 
Mcpherson et al,1996; Cremona et al, 1999; Guo et al, 1999).  
3) at the C-terminus, PRD domain comprises about 250 amino acid and 
contains at least five potential SH3 domain-binding consensus 
sequences (Mcpherson et al,1996). 
The 170 kDa isoform harbors an additional smaller PRD with at least 
three additional SH3 binding sites (Ramjaun and McPherson, 1996).  
Besides Grb2, the C-terminal region common to both SYNJ1 isoforms 
interacts with the SH3 domains of a variety of proteins implicated in 
endocytosis, subcellular targeting, and signalling such as endophilin, 
amphiphysin, syndapin/pacsin, intersectin, and many others (Heuvel et 
al, 1997; Itoh et al, 2005).  
The additional C-terminal tail of 170 kDa isoform contains binding sites 
for clathrin and AP2 via three types of binding motifs (WxxF, FxDxF, 
and DxF), and for Eps15 through asparagine-proline-phenylalanine 
(NPF) domain (Haffner et al,1997; Praefke et al, 2004).  
 
The missense Arg258Gln mutation found in PD localizes in exon 5 within the 
Sac domain. This arginine in position 258 is conserved among 18 different 
orthologs, in Synj2 and three human proteins containing Sac domain (Sac1, 
Sac2 and Fig4/sac3) suggesting that it could be critical for its function. 
Consistently, it has been demonstrated that the mutation impairs the 
phosphatase activity of Synj1 against PI monophosphates (Krebs et al. 2013). 
 
Fig. 13: Functional and interaction domains of the two major isoforms of SYNJ1.
The 145 kDa (top) and the 170 kDa (bottom) SYNJ1 isoforms harbor two functional
inositol phosphatase domains, an Nterminal Sac1 domain and a more central 5’-
phosphatase domain. Several protein-protein interaction domains are found in the C-
terminal part of the proteins: one or two PRD domains, AP2 binding motifs (WxxF,
FxDxF, and DxF, in pink), and Eps15 binding motifs (NPF: asparagine-proline-
phenylalanine, in blue). The homozygous mutation Arg258Gln, found in Parkinson’s
disease patients, is indicated in red. Numbers indicate the amino acid positions along
the proteins (from Drouet and Lesage 2014).
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Multiple functions 
Thanks its different functional domains and overall to the capacity to interact 
with different proteins, Synj1 has been implicated in different cellular process 
both in nerve terminals where it has been first discovered and in other cell 
types (Drouet and Lesage, 2014).  
First, Synj1 is implicated in synaptic vesicle recycling because it has been 
found localized in close proximity to clathrin- and dynamin coated endocytic 
intermediates in nerve terminals (McPherson et al.1994, David et al, 1996; 
Haffner et al. 1997). Further studies confirmed this role. Like dynamin Synj1 
interacts with amphysin and undergoes dephosphorylation after nerve 
terminal depolarization (McPherson, Takei et al, 1994; McPherson et al, 
1996). Moreover, it also interacts with endhophilin and together they are 
rapidly recruited to clathrin coated pits during prolonged stimulation (Heuwel 
et al, 1997; Perera et al, 2006). Recently, another study showed that upon 
endophilin-mediated recruitment (through an SH3-PRD interaction), SYNJ1 
promotes dephosphorylation of PI(4,5)P2 to endocytic sites (Milosevic et al. 
2011). Importantly, in neurons the dual phosphatase activity is required for 
efficient synaptic vesicle endocytosis and reavailability at nerve terminals 
(Mani et al. 2007). 
Furthermore, it has been shown that through its Sac-phopshatase activity 
Synj1 participates in actin cytoskeleton polymerization/depolymerization and is 
mostly required during brief neuronal stimulation (Kim et al. 2002; Mani et al. 
2007). Interestingly, it has been found that mutations in the homologues in C 
elegans (unc-26) and the inactivation of synaptojanin-like proteins in yeast, 
lead to increased levels of PI(4,5)P2, an increased number of clathrin-coated 
vesicles, and a hypertrophy of the actin-rich matrix at endocytic zones (Gad et 
al, 2000; Stefan et al, 2002) indicating that that the activity of Synj1 is essential 
for proper vesicle trafficking and coating/uncoating of endocytic vesicles in 
different organisms.  
In addition, another role has been identified for SYNJ1 post-synaptically: it is 
involved in the internalization of AMPA receptors in postsynaptic neurons 
(Gong and De Camilli, 2008) suggesting that Synj1 could participate in the 
signal transmission through postsynaptic reorganization. 
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Recent studies showed that Synj1 takes part in similar mechanisms in other 
cell types. Several studies in Zebrafish showed that Synj1 is required for 
vesicle recycling at ribbon synapses necessary for sensory transmission 
Indeed, in cone photoreceptors of Zebrafish vision mutant were found 
reduced numbers and abnormal distribution of synaptic vesicles within a 
dense cytoskeletal matrix have been found  (van Epps et al, 2004).  
Moreover, Synj1 seems critical for proper membrane trafficking in cones 
(Holzhausen et al, 2009; George et al, 2014). This role has yet to be 
confirmed in mammalian cells. Like in neurons, in podocytes Synj1 
participates in endocytosis with its interacting partners dynamin and 
endophilin by acting on phosphoinositides and actin filaments (Soda et al, 
2012). Recently, Synj1 has been reported as a potential regulator of allogenic 
T cell responses (Sun et al, 2013). 
All these data indicate that phosphoinositide metabolism plays an essential 
role in vesicle endocytosis and recycling. Hence, it is important to determine if 
the loss of Synj1 activity causes similar defects in humans as well as to 
understand if neurodegeneration in PD is caused by alteration of this process 
or by the lack of other pathways in which Synj1 could be involved. 
 
PHOSPHOINOSITIDES 
Phosphoinositides (PIs) are phosphorylated derivatives of phosphatidylinositol 
(PtdIns). Tough, these comprises less than 5% of total cellular lipids are 
essential components of cellular membranes and play key roles in many 
fundamental biological process (Di Paolo and De Camilli, 2006; Shewan et al, 
2011; Mayinger et al, 2012).  
PIs are concentrated on the cytosolic face of cellular membranes and rapidly 
diffuse within the plane of the membrane. Like other phospholipids, they 
consist of a glycerol backbone, which is esterified by two fatty acids and a 
phosphate that is attached to a polar head group, the cyclic polyol myo-
inositol (Fig. 14A).  
The PtdIns, the precursor of of phosphoinositides, is synthesized primarily in 
the endoplasmic reticulum (ER; Fig. 14B) and is then delivered to other 
membranes either by vesicular transport or via cytosolic PtdIns transfer 
proteins (Di Paolo and De Camilli, 2006). Reversible phosphorylation of the 
Fig. 14: Phosphoinositides synthesis and conversion. PtdIns and PIs contain an 
inositol head group linked to glycerol backbone, and two fatty acid chains. They are 
located in the inner leaflet of specific membranes and are reversibly phosphorylated at 
the D-3, 4, 5 positions of the inositol ring as indicated in red (A).  
The PtdIns is synthesized primarily in the endoplasmic reticulum (ER) and is then 
delivered through the Golgi to the specific subcellular compartments (B).  
Phosphoinositides can be interconverted between their many forms by the action of 
specific kinases (shown in green) and phosphatases (shown in red)  (C). 
Phosphorylation of phosphatidylinositol can give rise to seven different 
phosphoinositide forms: three mono-phosphorylated forms [PI(3)P), PI(4)P and 
PI(5)P], three bi-phosphorylated forms [PI(3,4)P2, PI(3,5)P2 and PI(4,5)P2] and the 
single tri-phosphorylated form, termed PI(3,4,5)P3.  
A! B!
C!
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myo-inositol head group at position 3, 4 and 5 gives rise to seven PI isoforms 
identified in eukaryotes cells: PI(3)P, PI(4)P, PI(5)P, PI(3,4)P2, PI(3,5)P2, 
PI(4,5)P2 and PI(3,4,5)P3 (Fig. 14). Among them, PI(4)P and PI(4,5)P2 are 
constitutively present in membranes and comprises the largest pool of cellular 
PIs, whereas is almost undetectable in most types of unstimulated cells 
(Lemmon and Ferguson, 2000; Saarikangas et al, 2010). 
Conversion between these isoforms is controlled by specific phosphoinositide 
kinases and phosphatases that regulate the balance of these lipids (Fig.14C, 
15). The concerted action of PI kinases and phosphatases, that attach or 
remove phosphate groups respectively, and phospholipases, that cleave 
lipids, results in the generation of unique PI enrichment in distinct intracellular 
membranes (Di Paolo and De Camilli, 2006; Kutateladze, 2010). Therefore, 
PIs can serve as a unique lipid signature or code, like Rab proteins, for 
cellular organelle identity (Fig. 15). Furthermore, within a given membrane, 
the localization of specific phosphoinositides can be heterogeneous, thus 
identifying specific sub-domains (Fig. 16). Hence, the differential intracellular 
distribution of phosphoinositides, together with their high turnover, makes 
these lipids optimal mediators of signalling events in all cellular compartments 
(Fig. 15, 16) (Di Paolo and De Camilli, 2006; Shewan et al, 2011). By acting 
as membrane designations for selective protein recruitment and assembly, 
PIs may trigger downstream signalling cascades. In particular, through the 
binding of their head groups to cytosolic proteins or cytosolic domains of 
membrane proteins they can regulate the function of integral membrane 
proteins (such as ion channels, and transporters, or recruit to the membrane 
cytoskeletal and signalling components (Di Paolo and De Camilli, 2006; 
Falkenburger et al, 2010; Zhang et al, 2012). Typically, binding of proteins to 
phosphoinositides involves electrostatic interactions with the negative charges 
of the phosphate(s) on the inositol ring. In some cases, adjacent hydrophobic 
amino acids strengthen the interaction (Lemmon, 2003). Protein that 
interacting with phosphoinositides can consist either of clusters of basic 
residues within unstructured regions, such as those found in many actin 
regulatory proteins (Yin and Jammey, 2003), or of folded modules, such as 
the pleckstrin homology (PH) domain (Lemmon, 2003; Balla et al, 2005). 
Whether these two types of interactions mediate different signalling cascades 
Fig. 15: Predominant subcellular localization of phosphoinositide species. 
PI(4,5)P2 and PI(3,4,5)P3 are concentrated at the plasma membrane. PI(3,4)P2 is 
mostly found at the plasma membrane and in the early endocytic pathway. PI(4)P is 
enriched at the Golgi complex, but also present at the plasma membrane. PI(3)P is 
concentrated in early endosomes and PI(3,5)P2 on late compartments of the 
endosomal pathway. The location of PI(5)P remains poorly characterized. 
Phosphorylation/dephosphorylation events occurring on each subcellular compartment 
are illustrated. In the ER, the conversion from phosphatidic acid (PA) to PtdIns 
involves more than one reaction (from Di Paolo and De Camilli 2006).!
Fig. 16: Subcellular distribution of the PIs and PI-metabolising enzymes. The 
localization of the different PI kinases (blue) and PI phosphatases (green), as well as 
the predominant PI species (as visualized by PI-binding protein domains) in the 
different cell compartments. It is noted that many of the PI-metabolising enzymes are 
present in more than one cellular compartment. PM, plasma membrane; EE, early 
endosome; SE: sorting endosomes; RE, recycling endosome; LY, lysosome; MVB/LE, 
multivesicular body/late endosome; PAS, pre-autophagosomal structure; PH, 
phagosome; TGN, trans-Golgi network; GC, Golgi complex; ER: endoplasmic 
reticulum; N, nucleus. !
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are unknown. So far, 11 PI-binding modules are known interact with unique 
PIs with variable affinity (Kutateladze, 2010). 
It is not surprising that the PI are emerging to be involved in many cellular 
processes such as membrane trafficking, cytoskeleton remodelling, signalling. 
The spatiotemporally regulated production and turnover of PIs is critical for PI 
functions. This is achieved by strict control of the subcellular distribution, 
membrane association and activity state of each of different kinases and 
phosphatases. Confirming their crucial role in cells, mice with mutation in the 
kinases or phosphatases that regulate levels of PI, die during embryonic life 
or develop severe neurological defects (Di Paolo and De Camilli, 2006; 
Vicinanza et al, 2008). An increasing number of human genetic diseases 
including myopathies and neuropathies are associated to mutations in 
enzymes regulating the turn over of PIs (Nicot and Laporte, 2008; Waugh 
2015).  
 
MULTIPLE ROLES OF PHOSPHOINOSITIDES 
 PI(4)P 
PI(4)P is produced by the phosphorylation of PtdIns by the PI 4-kinases 
(PI4Ks). Four different PI4K isoforms have been identified so far in mammals, 
and two of them, PI4KIIa and PI4KIIIb, are localized to the Golgi complex. 
Indeed, PI(4)P is enriched in the Golgi complex, where it plays a direct role  in 
controlling trafficking and Golgi morphology (De Matteis et al. 2007; D’Angelo 
et al, 2008). On the other hands, the deficiency of PI(4)P affects the function 
and the structure of Golgi complex. In yeast, mutations of the Golgi-localized 
PI 4-kinases PIK1 result in an accumulation of abnormal membrane 
intermediates (‘Berkeley bodies’) with impairment of transport to the plasma 
membrane (Odorizzi et al, 2004). Consistently, many PI4P-binding proteins 
have been identified at the Golgi complex, such as clathrin adaptors (AP1, 
GGAs, and epsin R) and lipid-transfer proteins (such as the four-phosphate-
adaptor proteins, FAPPs; the ceramide transport protein, CERT; and the 
oxysterol-binding protein, OSBP). The fact that AP1, the GGAs, FAPP1 and 
FAPP2 bind not only PI(4)P, but also the small GTPase Arf1 ensures the 
correct recruitment of these PI4P-binding proteins to the TGN (De Matteis et 
al. 2007; Levine et al. 2002). 
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Spatial restriction of PI(4)P to the Golgi complex is ensured by phosphatases, 
one of which is likely to be Sac1 (Guo et al. 1999). This protein is an ER- and 
Golgi-complex-associated phosphoinositide phosphatase, which may thus 
dephosphorylate PI(4)P when retrograde traffic occurs from the Golgi complex 
to the ER (Guo et al. 1999). Mutant sac1 yeast cells have high levels of 
PI(4)P, including high levels at the plasma membrane (Roy et al. 2004), which 
may be the indirect consequence of the excessive PI(4)P in early secretory 
compartments. 
 
PI(4,5)P2 
PI(4,5)P2 is produced by the phosphorylation of either PI(4)P by type I PI 
kinases or PI(5)P by type II PI kinases (Fig. 14-16) (Yin et al. 2003; Roth et al. 
2004).  
PI(4,5)P2 is mainly present at the plasma membrane (Falkenburger et al., 
2010). Small fractions of PI(4,5)P2 were are also detected at the Golgi and 
the nuclear envelope (Watt et al. 2002). 
Most cell surface PI(4,5)P2 is generated from PI(4)P. This lipid is delivered to 
the cell surface by membrane carriers derived from the Golgi complex and 
from recycling organelles, but is also produced locally at the plasma 
membrane. 
PI(4,5)P2 has an important role in endocytosis, because it functions as an 
important co-receptor for the recruitment and regulation of endocytic proteins 
selectively to the plasma membrane (Wenk and De Camilli 2004). Indeed, 
PI(4,5)P2 binds the endocytic clathrin adaptors (AP-2, AP180/CALM, epsin) 
and many other endocytic factors, including dynamin, which controls the 
vesicle fission (Wenk and De Camilli 2007; Owen et al. 2004). 
Plasma membrane PI(4,5)P2 is directly implicated in exocytosis. Specifically, 
this PI acts in controlling docking of synaptic vesicles prior to fusion (Holz et 
al. 2002). Several PI(4,5)P2 binding proteins play a role in this process 
including CAPS (calcium-activated protein for secretion), Syt1 
(Synaptotagmin-1) and rabphilin (Osborne et al. 2006).  
The Golgi complex PI(4,5)P2 is dephosphorylated by the 5- phosphatase 
OCRL that has been found mutated in the Lowe syndrome (Loi, 2006). OCRL 
ineracts with clathrin, the adaptor protein APPL and several Rab proteins and 
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is involved in the endocytic pathway and in trafficking betwenn endosomes 
and the TGN (Choudhury et al, 2005; Hyvola et al, 2006; Erdmann et al, 
2007). A recent report shows that OCRL deficiency causes accumulation of 
PI(4,5)P2 in early endosomes and induces an increase in endosomal F-actin 
(Vicinanza et al, 2011).  
 
PI(3)P 
PI3P is synthetized by class III PI-3 kinase first discovered in yeast as 
essential component of vacuolar sorting pathway, Vps34 (Leevers et al. 
1999).  The mammalian homologues of VPS34 is also involved in endocytic 
sorting (Mayinger et al, 2012). Also class II PI-3 kinases phosphorylate Pins to 
generate PI(3)P and are activated upon stimulation of tyrosine kinases 
receptor or G-protein coupled receptors (Falasca et al, 2009). Several 
phosphatases belonging to the myotubularin and myotubulayn-related 
proteins dephosphorylate the PI(3)P (Begley et al. 2005). 
PI3P is enriched on early endosomes (Fig 15) and participate to control the 
function of these organelles as sorting stations in the biosynthetic and the 
endocytic pathways (Efe et al. 2005, Di Paolo and De Camilli, 2006). 
P(3)P-binding modules, mainly FYVE and PX domains, are present in a 
variety of endosomal proteins, such as EEA1 and Hrs (Lemmon et al. 2003, 
Balla 2005, Birkeland et al. 2004). 
EEA1 is a Rab5 effector required for endosomal tethering and forms homo-
dimers through a coiled-coiled domain. EEA1 also interacts with SNARE 
proteins such as syntaxin-6 and syntaxin-13 at early endosomes (Simonsen 
et al. 1999; McBride et al. 1999). 
In contrast to EEA1, Hrs (hepatocyte growth factor-regulated tyrosine kinase 
substrate) binding to early endosomes independently of Rab5, but is 
dependnent on its FYVE domain (Raiborg et al. 2002). It is involved in the 
endosomal sorting of ubiquitinated membrane proteins through its clathrin-
binding domain and ubiquitin-binding domain (Raiborg et al. 2002). Moreover, 
Hrs has also been found associated with phagosomes in a PI(3)P-dependent 
manner  (Vieira et al. 2004). 
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PI(3,5)P2 
PI 3,5)P2 was first described in yeast where its synthesis is strongly induced 
by osmotic stress, but was also discovered as minor lipid component in non-
stimulated mammalian cells (Dove et al, 1997; Whiteford et al, 1997). Respect 
to other PIs, it is present in very low concentration (only 0.04/0.08% of total 
PI). 
As aforementioned, the presence of this PI is dependent on the action of PI3P 
kinase PIKfyve and phosphatase Fig4 that form a ternary complex with the 
adaptor protein ArPIKfive (Jin et al. 2008). 
The PI(3,5)P2 is enriched in the late compartments of endosomal pathway 
(late endosomes, multivesicular bodies, lysosomes) (Di Paolo and De Camilli 
2006). 
 
P(5)P 
PI(5)P is  the least characterized phosphoinositide. The mechanisms for 
PI(5)P biosynthesis are not well characterized. Theoretically, PI(5)P can be 
generated either by dephosphorylation of PI(3,5)P2 and PI(4,5)P2 or by 
phosphorylation of PI (Lecompte et al, 2008). The most established pathway 
is the generation of PI(5)P from PI(3,5)P2 by the 3-phosphatase myotubularin 
(Tronchere et al, 2004). 
It is not yet clear whether the PI(5)P is present in cells stably or it is just a 
transitional product. Some studies suggest that it plays a regulatory role in the 
nucleus through binding ING2 (nuclear protein inhibitor of growth protein-2) 
(Gozani et al, 2003).  
 
PI(3,4)P2 and PI(3,4,5)P3 
PI(3,4)P2 and PI(3,4,5)P3 are short-lived signalling molecules synthesized in 
response to extracellular stimuli and involved in cell proliferation and survival.  
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AIM OF THE STUDY 
The proper membrane trafficking that connects different intracellular 
organelles is essential to ensure the transport of various molecules to the 
correct compartments as well as to maintain the specific composition of the 
various compartments. This is crucial for homeostasis of eukaryotic cells and 
their vitality. Hence, it is not surprising that genetic defects of the molecular 
machinery regulating membrane trafficking can result in the development of 
different diseases. 
In this context, phosphoinositides (phosphorylated derivatives of 
phosphatidylinosititol) have emerged as important regulators of membrane 
trafficking by acting as membrane designations for selective protein 
recruitment and assembly, thereby triggering downstream signalling 
cascades. Thus, the levels of phosphoinositides might be finely regulated, in 
time and in the space, and they are critical for membrane homeostasis. This is 
achieved by strict control of the subcellular distribution, membrane association 
and activity state of each of different kinases and phosphatases. The proper 
balance between synthesis and degradation poses special challenges in 
nervous system, that indeed appears more sensitive to alterations of 
phosphoinositide metabolism as highlighted by the increasing number of 
human genetic diseases associated to mutations in enzymes regulating their 
turn over. 
Aim of my PhD project was to explore the role of two inositol-phosphatases, 
Fig4 and Synj1, in membrane trafficking and neurodegenaration in CMT4J 
and Parkinson neuropathies (where they have been found mutated, 
respectively). 
The rationale and the specific aims of each project are outlined below. 
  
Project 1: molecular basis of Charcot-Marie Tooth disease 4J (CMT4J) 
Fig4 removes the 5-phosphate from the phosphoinositide PI(3,5)P2 enriched 
in the endo-lysosomal compartments. Mutation of Fig4 falls out of catalytic 
site and the pathological mutant maintains its hydrolysing activity. Typical 
cellular feature is the accumulation of enlarged lamp-2 positive vacuoles. 
Because endo-lysosomal system plays a crucial role in the cellular 
homeostasis, it is likely that its dysfunction could lead to neurodegeneration. 
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However it is unknown which pathway of endo-lysosomal axis is affected by 
the loss of Fig4. 
Moreover, Fig4 seems play cell-specific role and this might contribute to 
CMT4J pathogenesis. However, the differential sensitivity of neuronal 
subtypes to Fig4 loss together with fact that Fig4 is expressed throughout 
development we could hypothesize that the Fig4 deficiency might affect some 
specific steps of neural differentiation. 
Specific aims of my project were to study:  
1) The localization and dynamics of Fig4 and its pathological mutants;  
2) The role of Fig4 in the endo-lysosome axis; 
3) The localization and the role of Fig4 in neural differentiation. 
 
Project 2: molecular basis of Parkinson’s disease 
Synj1 is an inositol-phosphatase containing two consecutive phosphatase 
domains, the Sac and the 5'-phosphatase domain responsible of different 
functions. With its Sac domain dephosphorylates predominantly PI 
monophosphates present in the membranes of Golgi apparatus and 
endosomes, while the central 5'-phosphatase domain dephosphorylates 
phosphatidylinositol bis- or trisphosphates localized in plasma membranes to 
activate downstream pathways. Thus, with this double enzymatic activity 
Synj1 could be involved in different pathways in different cellular context. 
Indeed, so far it has been implicated in different process: Synj1 is required in 
synaptic vesicle recycling, participates in actin cytoskeleton 
polymerization/depolymerization and more recently it seems implicated in the 
regulation of proper membrane trafficking in cone phothoreceptors.  
Pathological mutation is mapped in the Sac domain. However, the molecular 
mechanisms altered in the disease are still unknown. 
Specific aims of my project were to study:  
1) The expression and the localization of Synj1; 
2) The role of Synj1 in the endocytic pathway. 
!
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METHODS 
 
REAGENTS AND ANTIBODIES 
Primary antibodies used in this study include the following: rabbit polyclonal 
anti-Fig4 (Abcam) used for immunofluorescence and mouse monoclonal anti-
Fig4 (NeuroMab) used for western blot. Rabbit polyclonal anti-Synj1 (Abcam). 
Mouse monoclonal anti-Lamp1 (BD Phamigen) used for human cell lines and 
rat monoclonal anti-Lamp1 (Santa Crutz) used for mouse cell lines. Mouse 
monoclonal anti-Rab7 (Santa Crutz), mouse monoclonal anti-eea1 (Abcam) 
and mouse β3-tubulin (Sigma). 
Specifically for ESCs cells we used mouse Oct3/4 (Santa Cruz 
Biotechnology), rabbit Nanog (Calbiochem-EMD Biosciences) mouse GAPDH 
(Santa Cruz Biotechnology) and goat Sox1 (Santa Cruz Biotechnology).  
The secondary antibodies used for immunofluorescence were Alexa Fluor 488 
or 546 goat anti-mouse, rabbit, or rat IgG (Life Technologies).  
The HRP conjugated secondary antibodies used for Western blot analysis 
were from GE Healthcare. 
LysoTracker® Red DND-99 was from Molecular Probes. To stain nuclei we 
used DRAQ5® (1,5-bis{[2-(di-methylamino)ethyl]amino}-4, 8-
dihydroxyanthracene-9,10-dione) or DAPI (4',6-diamidino-2-phenylindole) 
(Cell Signaling). 
 
CELL CULTURES 
Cell lines 
MDCK cells were cultured in DMEM (Dulbecco’s modified eagle medium) 
supplemented with 5% FBS (Fetal Bovine Serum) while NIH3T3 cells in 
DMEM 5% CS (Calf Serum).  
HeLa and SH-SY5Y cells were maintained in RPMI-1640 with 10% FBS, 2mM 
L-glutamine. MO3.13 and NSC34 cells were cultured in DMEM 10% FBS, for 
NSC34 the medium was supplemented with 1mM L-glutamine and 1mM 
Sodium Pyruvate both from Life Technologies. 
All cells lines were maintained at 37°C in a saturated humidity atmosphere 
containing 95% air and 5% CO2. 
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Stem Cells 
E14Tg2a (BayGenomics) mouse ESCs were maintained on feeder-free, 
gelatin-coated plates in the following medium: Glasgow Minimum Essential 
Medium (GMEM, Sigma) supplemented with 2 mM glutamine, 1 mM sodium 
pyruvate, 1X non-essential amino acids (all from Invitrogen), 0.1 mM β-
mercaptoethanol (Sigma), 10% FBS (Hyclone Laboratories) and 103 U/ml 
Leukemia Inhibitory Factor (LIF, Millipore).  
ESCs were maintained at 37°C in a saturated humidity atmosphere containing 
95% air and 7% CO2 
 
Human fibroblasts 
Patients and control fibroblasts, obtained from skin biopsies, were given from 
De Michele and Bonifati laboratory. They were cultured in DMEM 
supplemented with 10% FBS and penicillin/streptomycin at 37 °C and 5% 
CO2. 
 
DIFFERENTIATION OF SH-SY5Y  
For differentiation of SH-SY5Y cells were seeded at an initial density of 104 
cells/cm2 in culture dishes. All trans-Retinal (Sigma) was added the day after 
plating at a final concentration of 10 µM in RPMI-1640 with 5% FBS to induce 
differentiation for seven days. The culture medium, supplemented with fresh 
additives, was changed every 2 days. 
 
DIFFERENTIATION OF ESCs 
Neural differentiation 
ESC differentiation into neuroectoderm was induced though SFEB formation. 
SFEBs were induced by placing 1x106 ESCs in 100-mm Petri dishes in the 
following differentiation medium: GMEM supplemented with 2 mM glutamine, 
1 mM sodiumpyruvate, 1 × nonessential amino acids, 0.1 mM β-
mercaptoethanol and 10% KSR. After 4 days, SFEBs were dissociated with 
trypsin and seeded in polylysine-coated dishes for neural differentiation.  
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Mesoderm differentiation 
Mesoderm differentiation was obtained through Embryoid-body (EB) 
formation. EBs were induced by placing 4x105 ESCs in 100-mm Ultra Low 
attachment dishes for 5 days in the following differentiation medium: GMEM 
supplemented with 2 mM glutamine, 1 mM sodiumpyruvate, 1 × nonessential 
amino acids, 0.1 mM β-mercaptoethanol and 15% FBS. 
 
GENE SILENCING 
Short hairpin RNAs (shRNAs) in the pLKO.1-puro vector (Thermo Scientific) 
were used for stable suppressing Fig4 and Synj1 (specific sh-RNA sequences 
are shown in the table below). 
Cells were transfected with shRNAs using Lipofectamine 2000 (Invitrogen) 
according to the manufacturer's protocol.  
Transduced cells lines were selected with 0.6 µg/ml of puromycin (Sigma), 
while ESCs with 2 ug/ml of puromycin. 
 
Specific Sh-RNA sequences of GFP, Fig4 and Synj1. 
sh-GFP  GGCACAAGCTGGAGTACAACTA  
sh-2555 Fig4 AACTTATGAGTTCTTGTTA human 
sh-2441 Fig4 CTCCAAGAGTAGACAGAAA mouse 
sh-2409 Fig4 TTGCTCAGATGGAGTTATA mouse 
sh-2542 Synj1 TGAACATATGCTAAGTAAAT mouse 
sh-2269 Synj1 AAATACTCTGAATAGTGATT mouse 
 
We silencing transiently ESCs with selected Stealth RNAi™ named 
MSS272220 and Stealth RNAi™ siRNA Negative Control, Med GC (used as 
negative control) using Lipofectamine 2000 (Invitrogen), according to the 
manufacturer's protocol. Stealth RNAi™ were from Life Technologies. 
 
PLASMIDS CONSTRUCTION AND MUTAGENESIS 
GFP-Fig4 and mutants  
The plasmid encoding human GFP-tagged Fig4 (RG207192) (GenBank 
accession number NM_014845) was purchased from Origene Technologies 
and was used also as template to generate the Fig4_I41T and Fig4-L17P 
mutants. Mutagenesis was performed by using the QuickChange Site-Direct 
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mutagenesis kit (Stratagene/Agilent Technologies). Primers were designed 
according QuickChange Site-Direct mutagenesis instruction and synthesized 
by the Ceinge Core Service Unit (Naples, IT). The mutations were confirmed 
by DNA sequencing performed by Ceinge Core Service Unit. 
 
WESTERN BLOT ANALYSIS 
Cells lines was grown on 100 mm petri dishes for 2 or 3 day, lysed with JS 
lysis buffer (Hepes pH 7.5 50mM, NaCl 150mM, glycerol 1%, Triton X-100 
1%, MgCl2 1.5mM, EGTA 5mM) with 15 µg/ml of protease inhibitor (Antipain, 
Pepstatin and Leupeptin all from Sigma).  
Undifferentiated and differentiated ESCs were lysed in a buffer containing 1 
mM EDTA, 50 mM Tris-HCl (pH 7.5), 70mMNaCl, 1% Triton and protease 
inhibitor cocktail (Sigma), and analyzed by western blot. 
Protein extracts was separated by SDS-PAGE and transferred onto PVDF 
membranes. Then were probed with the primary antibodies and proteins of 
interest were detected with HRP-conjugated secondary antibodies, visualized 
with the Pierce ECL Western blotting substrate (Thermo Scientific), according 
to the provided protocol. 
 
NUCLEAR/CYTOSOL FRACTIONATION 
Nuclear and cytoplasmic fractions were prepared with this method: 
The cells grown on petri dishes was scraped with buffer A (10 mM HEPES, 
1.5 mM MgCl2, 10 mM KCl, 0.5 mM DTT and 0.05% Igepal pH 7.9) leaved on 
ice for 10 min and centrifugated at 3000 rpm for 10 min then we removed 
supernatant and keep it (this contain everything except large plasma 
membrane pieces, DNA, nucleoli). 
Then, the pellet was resupended in buffer B (5 mM HEPES, 1.5 mM MgCl2, 
0.2 mM EDTA, 0.5 mM DT, 26% glycerol, pH 7.9; 300mM NaCl) and 
homogenized with Dounce. After 30 min on ice the sample was centrifuged  at 
24,000 g for 20 min and we took the supernatant. 
 
INTERNALIZATION ASSAY 
Transferrin receptor recycling assay 
For transferrin receptor recycling assay cells we used two approaches: 
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In the first approach cells were washed twice with serum-free medium, 
incubated with 10 µg/ml Alexa-Fluor-546 (Invitrogen) or FITC (Molecular 
Probes) conjugated transferrin at 37°C in RPMI 5% BSA and fixed at 5, 10, 15 
or 30 minutes. In the second approach the cells were first incubated 
transferrin for 10 min (pulse) at 37°C, the pulse medium was aspirated, and 
the cells were washed twice with serum-free medium to remove excess of 
unlabeled transferrin and then incubate with culture medium (chase), and 
fixed at 10, 20 and 30 min. 
 
EGFR internalization assay 
The cells was transiently transfected with an EGFR–GFP plasmid, after 48 
hours starved for 3h and stimulated at with EGF (100 ng/ml) at 37°C and fixed 
at 10, 20 and 30 minutes with 4% PFA.  
 
FLUORESCENCE MICROSCOPY  
Cells lines grown on coverslips, were washed with PBS, fixed with 4% 
paraformaldehyde and quenched with 50 mM NH4Cl. Primary antibodies were 
detected with Alexa Fluor 488 or Alexa Fluor 546 conjugated secondary 
antibodies.  
Undifferentiated ESCs and differentiate neurons were fixed in 4% 
paraformaldehyde and permeabilized with 0.2% Triton X-100 in 10% FBS 
(Invitrogen)/1% BSA in 1X PBS for 15’ at room temperature. Thus, the 
samples were incubated with primary antibodies and with an appropriate 
secondary antibody. SFEBs were collected at the indicated differentiation day 
fixed in 4% paraformaldehyde and dehydrated with increasing percentages of 
ethanol. Samples were embedded in paraffin, sectioned in 7-µm slices and 
mounted on glass slides. After rehydration and permeabilization, the samples 
were treated as previously described. 
For lysosome staining, cells were incubated for 1 h with Lysotracker (1:1000) 
in complete medium before fixing. 
Images were collected using a Zeiss Laser Scanning Confocal Microscope 
(LSM 510) equipped with a planapo 63× oil-immersion (NA 1.4) objective 
lens. In silencing experiments we used the same settings (laser power, 
detector gain). 
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RNA ISOLATION AND QUANTITATIVE REAL-TIME PCR (qPCR) 
For quantitative PCR total RNA was extracted by using TRI-Reagent (Sigma). 
The first-strand cDNA was synthesized according to the manufacturer’s 
instructions (M-MLV RT). qPCR was carried out with the 7500 Real-Time 
PCR System instrument and the Sequence Detection Systems (SDS) 1.4 
software (Applied Biosystems) using Power SYBR Green PCR Master mix 
(Applied Biosystems). The housekeeping GAPDH mRNAwas used as an 
internal standard for normalization, using 2-ΔΔCt method.  
 
Primers used for Real-Time PCR 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Nameᵃ Forward primer Reverse primer  
Sox1 CGCCATGCAAATCACCGCCG GGGCCCGGGCTGCCATTAAA 
Gapdh GTATGACTCCACTCACGGCAAA TTCCCATTCTCGGCCTTG 
Nanog TCAGAAGGGCTCAGCACCA GCGTTCACCAGATAGCCCTG 
Oct3/4 AACCTTCAGGAGATATGCAAATCG TTCTCAATGCTAGTTCGCTTTCTCT 
Fig4 CGACCAGTGTATGTGACCCT ATTTGCAACGTCACCCTCAC 
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RESULTS 
 
PROJECT 1: MOLECULAR BASIS OF CMT4J 
 
AIM 1. LOCALIZATION AND DYNAMICS OF FIG4 AND ITS 
PATHOLOGICAL MUTANTS 
 
Fig4 is expressed in different cell types and is mainly localized in the 
cytosol 
The intracellular localization of proteins has been proven to be important for 
their biological function and, regarding Fig4, it seems even more relevant 
since the precise regulation of PI levels, both in time and space, is achieved 
by strict control of their sub-cellular distribution and membrane association of 
kinases and phosphatase. 
Because Fig4 has a widespread expression and it could control different 
pathways in diverse cell types we decided to use as cellular model both 
neural and non-neural cells. Specifically we performed our analysis in: 
i) in HeLa cells and NIH3T3 cells (mouse embryonic fibroblasts) as non-
neural cells; 
ii) SH-SY5Y cells (from human neuroblastoma), MO3.13 cells (human 
glial oligodendrocytic hybrid), CAD (mouse cathecolaminergic 
neuronal cell line) and NCS34 (immortalized motor neurons) because 
the deficiency of Fig4 leads to distinct pathogenic changes in different 
neuronal cell subtypes (Ferguson et al. 2009, Katona et al. 2011, 
Vaccari et al. 2015). 
 
Firstly, we analyzed the expression of Fig4 in these different cell lines by 
western blotting assay using an anti-Fig4 antibody (Fig. 17). As you can see 
in the figure, Fig4 migrates in the gel according to the estimated molecular 
weight (about 103 kDa). As expected, Fig4 is expressed in both neural and 
non-neural cell lines. Furthermore, by indirect immunofluorescence assay, we 
analyzed the localization of Fig4 in the different cell lines. We found that in all 
cell lines Fig4 is localized mainly in the cytoplasm, preferentially in discrete 
punctate structures, which could be the compartments where the 
Fig. 17: Fig4 is expressed in different cell lines. HeLa, NIH3T3, SH-SY5Y and
MO3.13 cells were lysed with JS buffer (see methods) and resolved by SDS-PAGE
followed by immunoblotting with anti-Fig4 antibody. We used α-tubulin as loading
control. Molecular weights of standard proteins are indicated.
Fig. 18: In neural and non neural cells Fig4 is localized mainly in the cytosol in
discrete punctate structures. HeLa, SH-SY5Y, NIH3T3, MO3.13, CAD and NSC34
cells were fixed with 4% PFA, permeabilzed with 0.2% Triton X-100 and stained with a
specific anti-Fig4 antibody revealed with Alexa-488 conjugated secondary antibody.
Nuclei were labelled with DRAQ5 dye. Images were acquired by confocal microscopy.
Scale bar 5 µm.
HELA SH-SY5Y
NIH3T3 M03.13
NSC34CAD
Fig4
α-Tubulin
-100                  
-48          
-100                  Fig4
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phosphatase is working (Fig. 18). Interestingly, beyond to the cytosolic signal, 
in NIH3T3 and CAD cells Fig4 appears also distributed in a nuclear structure 
that resembles the typical nuclear bodies (Fig. 18). The fact that these cell 
lines derives from embryonic tissues where nuclear bodies are numerous 
supports that this signal is specific. We observed the same distribution in MEF 
(mouse embryonic fibroblast; data not shown) reinforcing this hypothesis. 
Moreover by a careful analysis of many images (as in the pictures in in Fig. 
18) a faint and diffuse nuclear signal of Fig4 is also evident in the other cells.  
We confirmed these results by biochemical nuclei/citosol fractionation assays 
(Fig. 19). Indeed, Fig4 is purified also in nuclear fraction at different extent in 
the different cell lines (Fig. 19). Hence, it will be important to understand 
whether this distribution is related to Fig4 functions and whether nuclear and 
cytosolic pool has different roles. Further, we will investigate this issue. 
 
Fig4 is enriched in Rab-7 positive compartments 
To better determine the intracellular localization of FIG4 we performed double 
immunofluorescence experiments labelling the different organelles of exocytic 
and endocytic pathway with specific markers. 
From morphological point of view, we observed that Fig4 signal is completely 
different from that of the exocytic compartments indicating the exclusion of the 
protein from these organelles (Fig. 20). Instead, Fig4-positive spots are 
localized in the areas occupied by the endocytic compartments and are in 
close proximity with these organelles (Figs 21-23). In particular, we found that 
both in neural and non-neural cells Fig4 does not partition either in early 
endosome (labelled with GFP-Rab5 or GFP-Rab4) or in recycling endosomes 
(labelled with GFP-Rab-11), while it is enriched in GFP-Rab7 compartments 
(Fig. 21). Similarly, about 5-7% of Fig4 co-localizes with Rab7 compartments 
labelled with a specific antibody (Fig. 22). Moreover, Fig4 results in close 
proximity with lamp1-compartments, but there is no co-localization (Fig. 23).   
Altogether these data indicate that Fig4 is recruited on Rab7-enriched 
compartments suggesting that Fig4 could controls their activity. 
 
 
Fig. 19: Fig4 is purified both in cytosol and nuclear fraction in different cell lines.
Nuclear are separated from cytosol by two sequential centrifugation (as described in detail in
methods). Total cell lysates (T), cytosolic fraction (C) and nuclear fraction were analyzed by
SDS-PAGE and western blotting by using an antibody anti Fig4. GAPDH were used as
cytosolic and nuclear marker respectively. Molecular weights of standard proteins are
indicated.
-100                  -100                  
NIH3T3   
GADPH
PARP -100                  
-35
HeLa
Fig4
TOTN CTOT N CTOT N C
CAD
TOT N C
-100                  
Bip Giantin
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MO3.13
Fig. 20: Fig4 is excluded from Endoplasmic Reticulum and Golgi. Cells were fixed
with 4% PFA, permeabilized with 0.2% Triton X-100, and stained by using specific
antibodies against Fig4 (green), Bip or Giantin (red) revealed with Alexa Fluor 488 and
546 secondary antibodies, respectively. Nuclei were labelled with DRAQ5 dye. Images
were acquired by confocal microscopy. Scale bar 5 µm. Insets show higher-
magnification.
SH-SY5Y
HeLa
GFP-Rab4GFP-Rab5 GFP-Rab11 GFP-Rab7
NIH3T3
GFP-Rab4GFP-Rab5 GFP-Rab11 GFP-Rab7
GFP-Rab11GFP-Rab5 GFP-Rab7
Fig. 21 : Fig4 partially colocalize GFP-Rab7 but not with GFP-Rab5 , GFP-Rab4 and GFP-Rab11.
HeLa, NIH3T3 and SH-SY5Y were transiently was transfected with cDNA coding for different GFP-
tagged Rab proteins. 48h after transfection the cells was fixed with 4% PFA, permeabilized with 0.2%
Triton X-100 and stained with the anti-Fig4 revealed with Alexa Fluor 546-conjugated secondary
antibody. Nuclei were labelled with DRAQ5 dye. Images were acquired by confocal microscopy. Scale
bar 5 µm. Insets show higher-magnification.
Fig4 DRAQ5 MERGERab7
HeLa
SH-SY5Y
M03.13
NIH3T3
Fig. 22: Fig4 results enriched in Rab7-positive compartments in different cell lines. Cells
were subjected to double immunofluorescence assay by using specific antibodies against Fig4
(green) and Rab7 (red). Cells were fixed, permeabilized with 0.2% TX-100 and stained with
primary and secondary antibodies. Nuclei were labelled with DRAQ5 dye. Images were acquired
by confocal microscopy. Squares show higher-magnification. Scale bar 5 µm.
HeLa NIH3T3 SH-SY5Y
Fig. 23 Fig4 does not co-localize with Lamp1. HeLa, SH-SY5Y, NIH3T3 and MO3.13
cells were subjected to double immunofluorescence by using specific antibodies
against Fig4 (green) and Lamp1 (red). Cells were fixed, permeabilized with 0.2% TX-
100 and stained with primary and secondary antibodies. Nuclei were labelled with
DRAQ5 dye. Images were acquired by confocal microscopy. Scale bar 5 µm. The
squares show the magnification of image.
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Pathological mutants appears unable to be recruited on intracellular 
compartments 
So far, how the function of Fig4 is impaired is unknown. As aforementioned, 
the pathological mutant Fig4I41T maintains its hydrolysing activity (Chow et 
al, 2007). To understand the molecular defect of pathological mutants we 
decided to investigate their localization and dynamics. To this purpose, we 
engineered two chimeric proteins, Fig4I41T and Fig4L17P, by site-directed 
mutagenesis of a GFP-tagged version of the wild-type Fig4 (from Origene). 
After transfection, we obtained stable clones of HeLa, NIH3T3 and SH-SY5Y 
cells expressing the chimeric proteins.  
As endogenous protein, GFP-Fig4 is localized in the cytosol in punctate 
structures indicating that GFP tag does not alter the behaviour of protein. 
Interestingly, we observed that both in HeLa and in SH-SY5 cells the two 
pathological mutants displayed a more diffuse intracellular signal (Fig. 24). 
These results suggest that mutants are unable to be recruited on intracellular 
compartments. Additionally, they suggest that the activity of Fig4 is strictly 
regulated through its localization.  
 
AIM 2. ROLE OF FIG4 IN THE ENDO-LYSOSOME AXIS 
 
Fig4 expression was silenced in HeLa, NIH3T3 and SH-SY5Y cells 
Various studies have reported that fibroblasts of CMT4J patients and plt mice 
display enlarged Lamp1/2 positive vacuoles (Chow et al, 2007; Zhang et 
Zhang et al, 2008; Katona et al, 2011), suggesting that the deficiency of Fig4 
leads to wide expansion and, likely, to dysfunction of the late 
endosome/lysosome compartments. Thus, to unravel how the specific 
pathway/pathways of the endo-lysosomal axis is/are regulated by Fig4 we 
decided to analyse the effects of its silencing on these compartments.  
To this purpose we used specific short hairpin RNAs (SH-2441 and SH-2409 
specific for mouse and SH-2555 specific for human, so called because of the 
position number in the library of short hairpins) and we stably transfected 
them in HeLa, NIH3T3 and SHSY5Y cells. As control we used an shRNA 
directed against GFP (SH-GFP, scramble). 
HeLa
GFP-Fig4 GFP-Fig4 L17PGFP-Fig4 I41T
SH-SY5Y
Fig. 24: Mutants of Fig4 display diffuse intracellular signal. Hela and SH-SH5Y stably
expressing Fig4-GFP, Fig4I41T-GFP and Fig4L17P-GFP were fixed and images were
acquired by confocal microscopy. Scale bar 5 µm.
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After puromycin selection we collected several pools and clones for each cell 
line. We evaluated the efficiency of silencing by western blotting and real-time 
PCR (data not shown).  For each cell line we obtained pools and some clones 
with different degree of silencing (from 30 to 70%) (Figs. 25-26). As 
expectable, clones resulted more silenced than pools. In particular, in HeLa 
cells the cl1 was the most silenced since Fig4 expression is reduced by 
approximately 65% (Figs. 25, 26), while in SH-SY5Y cells the cl8 displayed 
the best for the 42% of reduction (Figs. 25, 26). In NIH3T3 cells (2441 and 
2409) we got clones with a high degree of silencing with both shRNA (86% 
and 40%, respectively) (Figs. 25, 26). In addition, by immunofluorescence 
assay we confirmed these results and we found that not only in the clones, 
but also in the pool all the cells are homogenously silenced (data not shown). 
Moreover, by western blot analysis we verified that the silencing is stable 
(data not shown) and is maintained in the cells in culture until at least the 
fourth passage (we have not tested later ones) and we have always 
performed the experiments no later than the third passage in culture. 
 
The loss of Fig4 affects the endosome-lysosome compartments in 
different cell types  
Once obtained the Fig4-silenced cells, we investigated whether and how the 
loss of Fig4 affects the endo-lysosomal compartments. To this aim, firstly we 
analyzed the morphology and properties of endo-lysosomal compartments by 
immunofluorescence assays using different markers of the endocytic route 
(Figs. 27, 28).   
We have observed that in all three silenced cell lines lysosomal compartments 
are altered  (Figure 27). In fact, in Fig4-depleted cells lysosomes, labelled 
either with the Lysotracker dye or with lamp-1 antibody, are increased in 
number and appear as large dots with strong fluorescent signal (Figure 27). 
These results are in agreement with observations made in the fibroblasts of 
plt mice and patients (Chow et al, 2006; Zhang et al, 2008). 
Furthermore, we found that the absence of Fig4 also causes an alteration of 
early and late endosomes labelled with EEA1 and Rab7 antibodies, 
respectively (Fig. 28). Again they result more enlarged and the fluorescent 
signal of both markers are more intense (Fig. 28). Interestingly, in the NIH3T3 
NIH3T3
-100
-48
SH-2409 SH-2441 
-100
-48
Fig. 25: Fig4 expression is silenced by using short hairpin RNAs in different cell
lines. Lysates of NIH3T3, Hela and SH-SY5Y cells transfected with shRNA anti Fig4
(SH-2441, SH-2409, SH-2555), shRNA scramble (SH-GFP) were immunoblotted with
an anti-Fig4 antibody. We used α-tubulin as loading control. Molecular weights of
standard proteins are indicated.
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Fig. 26: Quantitation of silencing of the pool or clones in different cell lines.
Densitometric analysis of bands was performed with ImageJ. Percentage of Fig4 expression in
the different pools and clones respect to the amount of protein in scrambled cells (placed equal
to 100). Quantification of three independent experiments are shown (Error bars ± SD).
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cells, which have a major degree of silencing, EEA1-compartments appear as 
longer tubular elements in comparison to the punctate dots of control cells 
(Fig. 28).  
In contrast, the morphology of exocytic organelles (e.g. ER, Golgi) is 
unchanged in all Fig4-depleted cells (Fig. 29). All these data indicate that the 
loss of Fig4 affects the homeostasis of the whole endosome-lysosome axis 
both in neural and non-neural cells.  
 
The loss of Fig4 affects the intracellular trafficking along the endocytic 
pathway  
Beyond to be fundamental to counterbalance the anterograde flux of 
membranes, endosome-lysosome system connects different cell 
compartments and is an important station of sorting: internalized molecules 
from cell outside are recycled back to plasma membrane, targeted to 
degradation or transported toward early secretory compartment (as Golgi 
apparatus, ER).  
The above results highlight that Fig4 is critical for the homeostasis of the 
endo-lysosomal system; next, we asked whether Fig4 is also crucial for the 
function of these organelles. To this purpose, through endocytosis assays we 
assessed the trafficking of the transferrin receptor (TfR) and the EGF receptor 
(EGFR) that, after internalization from the plasma membrane, follow two 
different distinct itineraries: the recycling and degradation, respectively 
(Maxfield and McGraw, 2004; Thomas et al, 2013). We set up the best 
experimental conditions to monitor the trafficking of the two receptors. 
In the case of TfR cells were incubated with transferrin (conjugated to Alexa 
Fluor 546 or FITC) at 37°C for different times and then fixed and observed. 
We found that in Fig4-depleted HeLa cells the transferrin is internalized as in 
scrambled cells (Fig. 30). Albeit less drastic than at 30 minutes, at early 
timepoints (5 and 10 min) in silenced cells the signal of transferrin is more 
intense than in scrambled cells (Fig. 30). At 30 min, we appreciated a strong 
intracellular accumulation of the transferring and even more the Tf-positive 
compartment seems collapsed toward the centre of cells (Fig. 30).  
We obtained similar results when transferrin was added to cells for 10 minutes 
at 37°C (pulse), washed out and then cells were incubated for different times 
Fig. 27: The loss of Fig4 leads to an enlargement of endo-lysosomal compartments.
Scrambled and silenced cells were subjected to immunofluorescence assay by using anti-
Lamp1 antibody (left panel). Alternatively, cells were incubated with lysotracker for 1h at
37°C and then fixed. Images were acquired by confocal microscopy by using the same
settings (laser power, detector gain). Scale bar 5 µm.
HeLa
SH-SY5Y
NIH3T3
Fig4 shRNAscrambled shRNA
Lamp1
Fig4 shRNAscrambled shRNA
Lysotracker
scrambled shRNA Fig4 shRNA
NIH3T3
scrambled shRNA Fig4 shRNA
Rab7
HeLa
EEA1
SH-SY5Y
Fig. 28: The loss of Fig4 affects the morphology of both early and late
endosomes. After fixation scrambled and silenced cells cells were permeabilized and
stained with EEA1 (early endosome antigen 1) or Rab7 revealed with Alexa Fluor 546-
conjugated secondary antibody. Images were acquired by confocal microscopy by
using the same settings (laser power, detector gain). Scale bar 5 µm.
NIH3T3
HeLa
scrambled shRNA Fig4 shRNA mix6
Bip
Fig4 shRNA pool2
Giantin
Fig4 shRNA mix6scrambled shRNA Fig4 shRNA pool2
Fig. 29: The loss of Fig4 in Hela cells does not affects the morphology of Golgi
and Endoplasmic Reticulum. Scrambled and silenced Hela cells were subjected to
immunofluorescence assay. After fixation were permeabilized and stained with Giantin
or Bip primary antibodies revealed with Alexa Fluor 546-conjugated secondary
antibody. Images were acquired by confocal microscopy by using the same settings
(laser power, detector gain). Scale bar 5 µm. The squares show the magnification of
image.
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(chases) in fresh medium (data not shown). Thus, all these data indicate that 
the loss of Fig4 alters the recycling of TfR, which is internalized but does not 
recycle back to the surface.  
In addition, we observed the accumulation of transferrin also in SH-SY5Y cells 
as evident in single confocal sections and in 3D reconstruction (Fig. 31). This 
indicates that the regulation of the function of these compartments by Fig4 is 
a general mechanism active in all cell types. 
To monitor the intracellular traffic of the EGF receptor (EGFR) we used a 
chimeric protein in which the GFP (green fluorescent protein) is fused to the 
EGF receptor. For this purpose, scrambled or Fig4-silenced cells were 
transiently transfected with cDNA coding for GFP-EGFR and 48 hours after 
transfection, the cells were serum starved for 3h (as previously described, 
Dinnen and Ceresa, 2004; Puri et al, 2005) in order to prevent its ligand-
dependent internalization. As consequence, receptor accumulates at plasma 
membrane and indeed, as shown in Fig. 32, after starvation (time 0) the GFP 
signal is only present on the cell surface. Then cell were stimulated with EGF 
(100 ng/mL) at 37°C for different times.   
It is important to note that at time 0 the fluorescent signal is comparable in 
control and silenced cells indicating that the absence of Fig4 does not alter 
the biosynthetic transport of the receptor on the surface (Fig. 32). As 
expected, upon EGF stimulation EGFR is internalized, but in Fig4-depleted 
cells it progressively accumulates at the intracellular level as shown by the 
intense intracellular GFP signal respect to control cells (Fig. 32). These data 
indicate that the absence of Fig4 also alters the fate of the EGF receptor. The 
intracellular accumulation may be due to the dysfunction of lysosomes, which 
could be unable to degrade proteins.  
 
AIM 3. ROLE OF FIG4 IN NEURAL DIFFERENTIATION 
 
Fig4 is expressed in all the stages of neural and mesodermal 
differentiation 
The fact that in plt mice the loss of Fig4 leads to distinct pathogenic changes 
in different neuronal cell subtypes (Ferguson et al, 2009; Katona et al, 2011) 
5’
30’
Fig4 shRNAscrambled shRNA
Time (min)
Fig. 30: The loss of Fig4 affects the trafficking of TfR in HeLa cells. Scrambled
and silenced cells were incubated at 37°C with FITC- conjugated transferrin (Tf) for
each time, cells were fixed with 4% PFA. Images were acquired by confocal
microscopy by using the same settings (laser power, detector gain). Scale bar 5 µm.
The squares show the magnification of image.
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Fig. 31: The loss of Fig4 affects the trafficking of TfR in SH-SY5Y cells. Internalization
assay of Alexa Fluor 546 conjugated transferrin (Tf) in scrambled and Fig4 silenced SH-
SY5Y cells was carried out as in Fig. 30. An xy section toghether the 3D reconstruction are
shown. Confocal images were acquired from the top to the bottom of cells by using the same
settings (laser power, detector gain). Scale bar 5 µm.
5’
30’
Fig4 shRNAscrambled shRNA
Time (min)
Fig. 30: The loss of Fig4 affects the trafficking of TfR in HeLa cells. Scrambled
and silenced cells were incubated at 37°C with FITC- conjugated transferrin (Tf) for
each time, cells were fixed with 4% PFA. Images were acquired by confocal
microscopy by using the same settings (laser power, detector gain). Scale bar 5 µm.
The squares show the magnification of image.
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Fig. 31: The loss of Fig4 affects the trafficking of TfR in SH-SY5Y cells. Internalization
assay of Alexa Fluor 546 conjugated transferrin (Tf) in scrambled and Fig4 silenced SH-
SY5Y cells was carried out as in Fig. 30. An xy section together the 3D reconstruction are
shown. Confocal images were acquired from the top to the bottom of cells by using the same
settings (laser power, detector gain). Scale bar 5 µm.
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Fig. 32: The loss of Fig4 affects the trafficking of EGFR. Scrambled and Fig4-
silenced HeLa cells were transiently transfected with cDNA coding for GFP-EGFR. 48
h after transfection, cells were serum starved for 3h, then treated with EGF (100
ng/mL) and fixed at the indicated times. Images were acquired by confocal microscopy
by using the same settings (laser power, detector gain). Scale bar 5 µm.
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and the loss of Fig4 is implicated in the defects of myelin sheath formation 
(Vaccari et al, 2014) suggesting that Fig4 might play cell-specific role and, 
likely, this might contribute to CMT4J pathogenesis. However, the molecular 
basis for the differential sensitivity of neuronal subtypes to loss of Fig4 is 
unclear.  
To understand the role of Fig4 in neural differentiation we will take advantage 
of mouse embryonic stem cells (ESCs) differentiation, which are able, under 
specific conditions, to differentiate in any type of cell of an adult organism. In 
collaboration with Dr. Silvia Parisi, who set up protocols to specifically 
differentiate ESCs cells (Parisi et al, 2010) we analyzed the expression and 
distribution of Fig4 in stem cells and during neuronal differentiation by using 
double or triple immunofluorescence assays (Fig. 33). 
We found that Fig4 is expressed in ESCs as wells as during the early stages 
of differentiation (SFEBS, serum free embryoid bodies) and in terminally 
differentiated neural subtypes (Fig. 33). Indeed, Fig4 is present in the Oct3/4 
(stemness markers) positive cells, indicating that Fig4 gene is already 
expressed in stem cells (Fig. 33). We obtained similar results in Human 
embryonic stem cells (Fig. 33). Moreover, we found that Fig4 is expressed in 
all cells of SFEBS programmed toward neuorectodermal differentiation (which 
contain about 90% neuroectodermal cells, 8% mesodermal cell, 1-2% stem 
cells) at comparable extent. Indeed it is present both in Oct3/4 and Sox1 
(marker of early neural differentiation) positive cells. Altogether these data 
indicate that Fig4 is expressed in the early stages of neural differentiation 
(Fig. 33). 
 Fig4 is localized mainly in the cytoplasm of ESCs and SFEBS preferentially in 
discrete punctate structures (Fig. 33). Interestingly, in ESCs it is also evident 
signal of Fig4 in nuclear areas (Fig. 33) resembling the nuclear structures also 
observed in cell lines of embryonic origin (Fig. 18).  
Finally, in post-mitotic-neurons (after 13 days of ESCs differentiation) labelled 
with β3-tubulin (neuron marker) and GFAP (astrocyte marker) we found that 
Fig4 is expressed both in neurons and in astrocytes. In both cell types it is 
localized on the cell body and in neural extensions.  
ESCs
Fig4 DRAQ5 MERGEOct3/4
Human ESCs
Fig4 Oct3/4 MERGESox1
SFEBs
Fig4 DRAQ5 MERGEβ3tub
Fig4 DRAQ5 MERGEGFAP
Mouse ESCs-
derived neurons
(ESC-derived 
Neurons)
Fig. 33: Fig4 is expressed in Embryonic stem cells and during all the stages of the
neural differentiation. Double or triple immunofluorescence was carried out in mouse
and human Embryonic stem cells (ESCs) as well as in SFEBs and in mouse ESC-
derived neurons by using specific markers of stemness (Oct3/4) or neural differentiation
(Sox1 and β3tubulin). To identify astrocytes, differentiated neurons were labelled with
GFAP. Nuclei were stained with DRAQ5. Images were acquired by confocal microscopy.
Scale bar 10 µm.
Mouse ESCs-
derived neurons
(ESC-derived 
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We also evaluated the expression levels of Fig4 during the neural 
differentiation by western blotting (Fig. 34A). We found that the expression 
follows a peculiar kinetic: the levels of FIG4 are high in ESCs, decrease in 
SFEBS, and then increase again when the cells differentiate into neurons 
(Fig. 34A). Same kinetic was found by analyzing the levels of Fig4 transcripts 
by real-time PCR (Fig 34B). Interestingly, differently from neural 
differentiation, during mesodermal differentiation the levels of Fig4 decrease 
respect to the ESCs and then both transcripts and proteins remain stable over 
time (Fig. 35). In addition, the Fig4 expression during the diverse stage of 
mesodermal differentiation is lower than we observed during neural 
differentiation (Fig. 35). 
 
Fig4 is essential in the early phases of neural differentiation 
At this point, we asked in which steps of differentiation Fig4 could play a 
critical role. To this aim, we silenced the FIG4 expression in ESCs cells by 
using specific shRNAs, which are stably transfected in the cells. We collected 
a pool of ESCs transfected with a good degree of silencing (about 60-65%, 
Fig. 36 upper panel).We investigated the effect of loss of Fig4 in neural 
differentiation by analyzing the expression of Oct4 and Sox1 assayed by real-
time-PCR (Fig 36, middle panel). Interestingly, the loss of Fig4 correlates with 
altered expression of stemness and and early neural markers (OCT4 and 
SOX1, respectively). Indeed, we found that in Fig4-depleted ESCs the levels 
of Oct4 are lower than in control cells, indicating a rapid loss of stemness (Fig. 
36). Consistently, the expression of Sox1 increases earlier upon Fig4 
silencing (Fig. 36). Although the silencing of Fig4 is lost over time, its absence 
in ESCs is sufficient to alter the equilibrium between stemness and 
differentiated proteins. These results suggest that the loss of Fig4 induces 
earlier differentiation.  
Because of technical limit that ESCs lost the silencing of Fig4 during the 
culture, we decide to silence transiently the expression of Fig4 by using 
Stealth RNA and analyzed the effect of Fig4 absence in the early stage of 
neural differentiation. As shown in Fig. 37, the expression of Nanong, another 
marker of stemness, is reduced in Fig4-depleted cells, in agreement with 
results obtained with stable interference (Fig. 36).  
Fig. 34: Both Fig4 proteins and transcripts were expressed at different extent
during all stages of neural differentiation. ESCs were induced to neural
differentiation (see methods). After each time point cells were collected and processed
for western blot (A) or for RT-PCR analysis (B). Samples were revealed with a specific
anti-Fig4 antibody. We used GAPDH as loading control. Molecular weights of standard
proteins are indicated (A). RT-PCR analysis (B) shows the mRNA expression levels of
Fig4 (B). Error bars represent standard deviation of experimental triplicates.
0,000
0,005
0,010
0,015
0,020
0,025
0,030
0,035
0,040
E14 sfebs 2d sfebs 4d neuro 7d neuro 10d neuro 13d
0 2 4 7 10 13
GAPDH
Fig4 -100
-35
Day
ESCs SFEBs NEURONS
A
B
2D sfebs 4D sfebs 7D neuroSCs Days10D neuro 13D neuro
Fi
g4
 m
R
N
A 
re
la
tiv
e 
le
ve
ls
0 2 5 9
GAPDH
Fig4 -100
-35
Day
ESCs EBs MESO
Fig. 35: Fig4 is expressed at low level during mesodermal differentiation. ESCs
were induced toward mesodermal differentiation (see methods). At each time point,
cells were processed for western blot and RT-PCR analysis as described in Fig.34
Molecular weights of standard proteins are indicated (A). Real time PCR shows the
mRNA expression levels of Fig4 (B). Error bars represent standard deviation of
experimental triplicates. EBs: Embryoid bodies; meso: mesoderm.
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Fig. 36: The depletion of Fig4 in ESCs correlates with the altered expression
levels of stemness and neural differentiation markers. ESCs were stably
transfected with a short hairpin RNA against Fig4 (sh-2441) or anti-GFP as control (sh-
GFP). Western blot analysis shows that Fig4 is silenced at great extent (A). α-tubulin
was used as loading control. Molecular weights of standard proteins are indicated (A).
Real time PCR (B) show the mRNA expression levels of Fig4, stemness (Oct4) and
early neural differentiation (Sox1) markers. Error bars represent standard deviation of
experimental triplicates.
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Fig. 37: Fig4 depletion in ESc correlates with an alteration of the expression
levels of Nanog. ESCs were transiently transfected with specific Stealth against Fig4
(Fig4 siRNA) or with an unspecific sequence as control (scramble siRNA). The level of
Fig4 and Nanog (stemness marker) were analyzed. GAPDH was used as loading
control. Molecular weights of standard proteins are indicated.
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All these data suggest that Fig4 is essential in the early phases of neural 
differentiation. 
Unfortunately, because the silencing of Fig4 is lost over time, so far we did not 
get any data on the role of Fig4 in the late stages of neural differentiation. We 
are currently set up the best conditions to silence Fig4 expression later 
(already during neuroectodermal differentiation) by using Stealth RNA to 
analyse this issue. 
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PROJECT 2: MOLECULAR BASIS OF PARKINSON’S DISEASE 
 
AIM 1. SET UP CELLULAR MODELS  
 
Synj1 is expressed in different cell lines  
First aim of project 2 was to set up the good cellular model to subsequent 
studies. To this purpose, first we analysed, by western blotting, the expression 
of Synj1 in various cell types (neural and non-neural) because the protein has 
a broader tissue distribution (Ramjaun and McPherson, 1996) as also 
confimed by recent analysis of mRNA expression profiles made on human 
and mouse tissues (GeneAtlas). 
As shown in Figure 38, Synj1 migrates in the gel as two bands (slower and 
faster) corresponding to the molecular weight of the two isoforms of the 
protein (170 and 145 kDa, respectively). In agreement with previous data 
(Ramjaun and McPherson, 1996; Haffner et al, 1997), in neuronal cells only 
the 145 kDa isoform is present, while in the other cell types both isoforms are 
present at different extent (Fig. 38).  
Since the expression is quite comparable in the different cell lines, for the 
following studies we used as cell model: i) Hela cells as a non-neural cell 
because they are easy manipulate (e.g., easy to transfect, etc.); ii) SH-SY5Y 
cells as neural type, constituting also a good model of the disease because 
these cells have many features of dopaminergic neurons (such as they 
produce dopamine). 
 
Synj1 is localized in the cytoplasm mainly along the plasma membrane  
By indirect immunofluorescence assay, we analysed the localization of Synj1 
in Hela and SH-SY5Y. We found that in both cells lines, Synj1 is localized in 
the cytoplasm mainly along the plasma membrane (Fig. 39) in agreement with 
the fact that it is involved in synaptic vesicle endocytosis (McPherson et al, 
1994; McPherson, Takei, et al, 1994). In addition, Synj1 is also present in 
intracellular discrete punctate structures more distant from surface (Fig. 39), 
which could be other sites where the enzyme acts. Moreover, it is interesting 
to note that in both cells lines there is a weaker signal at the level of the 
Synj1
-180
-135
α-Tubulin -48
Fig. 38: Synj1 is expressed in different cell lines. MDCK, HeLa, NIH3T3 and SH-
SY5Y cells were lysed and resolved by SDS-PAGE. Samples were revealed by using
an specific antibody anti- Synj1. α-tubulin was used as loading control. Molecular
weights of standard proteins are indicated.
HeLa
SH-SY5Y
Fig. 39: Synj1 is localized mainly in the cytoplasm along the plasma membrane
both in HeLa and SH-SY5Y cells. Cells were fixed, permeabilzed with 0.2% Triton X-
100 and stained with an anti-Synj1 antibody revealed with Alexa Fluor 546-conjugated
secondary antibody. Images were acquired by confocal microscopy. Scale bar 5 µm.
Squares show the magnification.
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endoplasmic reticulum as demonstrated by the nuclear envelope positivity 
(Fig. 39). 
Furthermore, we analysed the localization of Synj1 in SH-SY5Y cells induced 
to differentiation by treatment with retinoic acid or its analogue (such as 
retinal) as previously described (Xie Hong-Rong et al, 2010). Although SH-
SY5Y cells have the characteristics of neuronal cells, following to the 
treatment they can differentiate even more assuming the distinctive 
morphological and biochemical properties of the neurons in the human brain. 
The cells, cultured in low-serum medium (5% instead of 10 %) and in the 
presence of retinoic acid (or retinal, 10 µM), cease to proliferate and start to 
differentiate as shown by the formation of long neurites (Fig. 40A). We 
monitored the cells day by day evaluating their morphological characteristics 
over time (some representative images in Figure 40A). As it can observe, the 
cells change morphology over time by acquiring the peculiar neuronal 
morphology showing long neurites (Fig. 40A). In according to previous studies 
(Xie Hong-Rong et al, 2010), we also found that seven days after treatment 
cells reach the maximum differentiation state and at this time cells were 
subjected to double immunofluorescence assay using an anti-Synj1 antibody 
(in green) and an anti β3-tubulin (red), which is a typical marker of post-mitotic 
neruons. We found that in differentiated cells Synj-1 is localized in discrete 
punctate structures mainly along neurites (Fig. 40B).  
 
 
AIM 2. ROLE OF SYNJ1 IN THE ENDOCYTIC PATHWAY 
 
Synj1 expression was silenced in HeLa and SH-SY5Y cells 
Various studies demonstrated that Synj1 together with its interacting partners 
dynamin and endophilin is implicated in synaptic vesicle endocytosis 
(McPherson, Takei et al, 1994; McPherson et al, 1996; Milosevic et al, 2011; 
Soda et al, 2012). Moreover, recent findings carried out in cone 
photoreceptors of Zebrafish highlighted that Synj1 could be also critical for 
proper membrane trafficking (Holzhausen et al, 2009; George et al, 2014), but 
this new role has yet to be confirmed in mammalian cells. Thus, to better 
understand the cellular pathways in which Synj1 could be involved and to 
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Fig. 40: Synj-1 is localized mainly in the cytoplasm along neurites in differentiated SH-SY5Y. Cells were
coltivated in low-serum medium (5%) with all trans-Retinal (10 μM) for one week and observed under phase-
contrast microscope. The photos show the differentiation state at 1, 4 and 7 days (A). After 7 days of all trans-
Retinal treatment, the cells were fixed and subjected to double indirect immunofluorescence using antibodies
against Synj1 and β3-tubulin revealed respectively with Alexa-488 and Alexa-546 conjugated secondary
antibodies. Images were acquired by confocal microscopy. Scale bar 5 µm.
.
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identify which of these putative pathways is altered in the PD, we decided to 
silence the expression of Synj1 by stable transfection of specific sh-RNAs 
(2269, 2542, 2231, and 2372) in HeLa cells and in SH-SY5Y cells. After 
puromycin selection we collected several pools and clones for each cell line 
and we evaluated the efficiency of silencing by western blotting.  The sh2231 
and sh2372 resulted not efficient because cells were not silenced or to a very 
low percentage (data not shown). We have obtained pools and clones with 
different degree of silencing (from 30 to 80%) in the case of 2269 and 2542 
shRNA for both cell lines (Figs. 41, 42). In particular, in the case of sh2269 
pool 1 and 2 were the most silenced (75-80%), while in the case of sh2542 cl1 
resulted the most silenced because Snj1 expression was reduced of about 
70% (Figs. 41, 42). In most of the experiments we used the pool with best 
degree of silencing because more representative of the cell population. In 
addition, it is important to note that it is reduced the expression of both 
isoforms of the protein. In SH-SY5Y cells the silencing was less efficient than 
in HeLa cells (Figs. 41, 42) and this is probably due to the considerable 
difficulties to transfect these cells. In subsequent studies We used pool 2 in 
the successive studies.  
As in the case of Fig4 silencing, we found that cells are homogenously 
silenced and the silencing of Synj1 expression is maintained in the cells in 
culture over time (at least the fourth passage in culture).  
 
The loss of Synj1 drastically affects the early endosomes, but not the 
late endosomes 
Once obtained Synj1 silenced cells, we asked whether the absence of Synj1, 
and therefore the loss of its activity, affects the endo-lysosomal compartments 
and on which of these compartments. To this purpose, we analyzed the 
morphology and properties of endo-lysosomal compartments by 
immunofluorescence assays using different markers of the endocytic route 
(Figs. 43-45). 
We found that both in HeLa and SH-SY5Y cells the loss of Synj1 drastically 
affects the morphology of early endosomes labelled with EEA1 (Fig. 43 and 
44, respectively). Indeed these compartments appear enlarged and more 
abundant (Figs. 43, 44). Furthermore, in both cell lines the fluorescent signal 
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Fig. 41: Synj1 expression is silenced by using short hairpin RNAs in different cell lines.
Lysates of Hela and SH-SY5Y cells transfected with shRNA anti Synj1 (SH-2542, SH-2269),
shRNA scramble (SH-GFP) were immunoblotted with an anti-Synj1 antibody. We used α-tubulin
as loading control. Molecular weights of standard proteins are indicated.
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Fig. 42: Quantitation of silencing of the pool or clones in different cell lines.
Densitometric analysis of bands was performed with ImageJ. Percentage of Synj1
expression in the different pools and clones respect to the amount of protein in
scrambled cells (placed equal to 100). Quantification of three independent experiments
are shown (Error bars ± SD).
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is much more intense, as it is even more evident in the 3D reconstruction 
(Figs. 43, 44). 
On the contrary, we observed that the silencing of Synj1 does not alter the 
morphology of late endosomes that were labelled with an anti-Rab7 antibody 
(Fig. 45).  
We obtained the same results by analyzing the fluorescence of GFP-tagged 
Rab proteins (GFP-Rab5 and GFP-Rab 7) used to stain these compartments 
(data not shown). 
These data clearly indicate that the loss of Synj1 alters exclusively the 
homeostasis of early endosomes. In addition, the fact that the silencing of 
Synj1 expression has similar effects in fibroblasts and neuronal cells suggests 
that the protein plays an essential role in the control of early endosomal 
compartments in all cell types. 
 
The loss of Synj1 slightly alters lysosomal compartments 
Then, we investigated the effect of silencing of Synj1 expression on the 
lysosomes labelling these organelles by using an anti-lamp1 antibody or the 
Lysotracker dye (Fig. 46). 
We found that, with both staining, lysosomes appear more numerous and as 
fluorescent spots with more intense signal in HeLa and SH-SY5Y silenced 
cells (Fig. 46; upper and lower panels, respectively), indicating an expansion 
of this compartment. If this is due to the altered membrane trafficking from 
early endosomes or is a consequence of the increased level of autophagy 
(found in neurodegenerative disease) is to be clarified. 
 
The loss of Synj1 affects the recycling trafficking 
The above results indicate that Synj1 is critical for the homeostasis of the 
early endosomes. Thus, we asked if the loss of Synj1 inhibits the functions of 
these compartments.  To this aim, through endocytosis assays we analyzed 
the trafficking of the transferrin receptor (TfR), which upon internalization 
recycled back to the cell surface. 
In a first approach, the cells were incubated with AlexaFluor 546 conjugated-
transferrin at 37°C for different time (5, 10, 15 and 30 min) and then fixed and 
observed. We observed that in Synj1-depleted HeLa cells TfR progressively 
Scrambled shRNA Synj1 shRNA Pool 1A
Fig. 43: Loss of Synj1 affects the morphology of early endosomes. Scrambled and
silenced cells were fixed permeabilized and stained with EEA1 (early endosome antigen
1) revealed with Alexa Fluor 546-conjugated secondary antibody. Confocal images were
acquired from the top to the bottom of cells by using the same settings (laser power,
detector gain). Scale bar 5 µm. Single confocal sections (A) or 3D reconstruction (B) are
showed.
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Scrambled shRNA Synj1 shRNA
SH-SY5Y
Fig. 44: Loss of Synj1 affects the morphology of early endosomes. Scrambled
and silenced cells were fixed permeabilized and stained as in Fig.43. Confocal images
were acquired from the top to the bottom of cells by using the same settings (laser
power, detector gain). Scale bar 5 µm. Single confocal sections (upper panel) or 3D
reconstruction are shown.
Scrambled shRNA Synj1 shRNA
SH-SY5Y
HeLa
Fig. 45: Loss of Synj1 does not alter the morphology of late endosomes. After
fixation cells were permeabilized and stained with Rab7 antibody revealed with Alexa
Fluor 546-conjugated secondary antibody. Images were acquired by confocal
microscopy by using the same settings (laser power, detector gain). Scale bar 5 µm.
Scrambled shRNA Synj1 shRNA
Fig. 46: Loss of Synj1 alters lysosomal compartments in HeLa and SH-SY5Y. Lysosomes of 
HeLA (A) and SH-SY5Y (B) were labeled by using an anti-Lamp1antibody revealed with Alexa-546 or 
Lysotracker Dye as described in Fig. 27. Images were acquired by confocal microscopy by using the 
same settings (laser power, detector gain). Scale bar 5 µm. The squares show magnification of image.!
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accumulate at the intracellular level, as more evident after 30 min of 
incubation (Fig. 47), indicating that its recycling to surface is impaired. 
In a second approach, cells were incubated with transferrin at 37°C for 10’ 
(pulse), washed to remove the unbound transferrin, and then incubated at 
37°C for different times in the standard culture medium (chase). Also with this 
assay we found intracellular accumulation of transferrin as shown in the single 
confocal sections (Fig. 48, upper panels) and in the 3D reconstruction (Fig. 
48, lower panels) both in HeLa and SH-SY5Y silenced cells.  
Furthermore, we also investigated the trafficking of the EGF receptor upon 
ligand stimulation and we found that the kinetic of internalization is 
comparable between control and silenced cells (data not shown). 
Altogether these results indicate that the activity of Synj1 is crucial for the 
function of early/recycling compartments. 
 
Patient fibroblasts display the same alterations found in the cell lines  
To determine whether the dysfunction of the early endocytic pathway is the 
cause of this genetic form of PD where Synj1 is mutated, we repeated the 
experiments on patients fibroblasts. First, we performed an 
immunofluorescence assay by using an anti-EEA1 antibody to label the early 
endosomes. In agreement with results obtained in the silenced cells, we found 
that in the patient fibroblasts early endosomes are expanded, as shown by the 
presence of larger and more intense fluorescent spots (Fig. 49, upper panel). 
Moreover, we observed that the recycling to the surface of the transferrin is 
impaired in patient fibroblasts (Fig. 49, lower panel). Indeed, the transferrin is 
greatly accumulated inside the cells of patients respect control fibroblasts 
(Fig. 49, lower panels). 
Altogether these results indicate that the loss of Synj1 or the presence of a 
mutated form of the protein (in patients) causes an alteration in the 
early/recycling endosomal compartments. Therefore, these data highlighted 
that an alteration of homeostasis of endosomal compartments might cause 
the disease. 
 
 
 
Fig. 47: The loss of Synj1 affects the trafficking of TfR in Hela cells. Internalization assay of
Alexa Fluor 546 conjugated transferrin (Tf) in scrambled and Synj1 silenced cells. After incubation
with Tf the cells were fixed at the indicated times. Images were acquired by confocal microscopy by
using the same settings (laser power, detector gain). Scale bar 5µm.
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Scrambled shRNA
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HeLa SH-SY5Y
Fig. 48: The loss of Synj1 leads to intracellular accumulation of Transferrin. Cells were
incubated with Alexa Fluor 546 conjugate transferrin at 37°C for 10 min (pulse), washed, and
incubated in the standard culture medium at 37°C for different times (chase). In the figure single
confocal section (xy) or 3D reconstruction of pictures token after 10 min of chase are shown. Were
used the same settings (laser power, detector gain). Scale bar 5 µm.
Scrambled shRNA Synj1 shRNA Scrambled shRNA Synj1 shRNA
Fig. 49: In patient fibroblasts early endosome are alterated as well as the trafficking
of transferrin. Health control (left panel) and patient fibroblast (middle and right panels) and
healthy control were fixed, permeabilized and stained with EEA1 antibody and revealed by
Alexa Fluor 546-conjugated secondary antibody (A). The fibroblasts were incubated with
FITC-conjugated transferrin (Tf) for different times and fixed. The image after 20 min of Tf
incubation are shown. The images were acquired by confocal microscopy by using the
same settings (laser power, detector gain. Scale bar 5 µm.
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DISCUSSION  
 
PROJECT 1: MOLECULAR BASIS OF CMT4J 
Mutations in the in the inositol-phosphatase Fig4 cause the rare autosomal 
recessive Charcot-Marie-Tooth peripheral neuropathy type 4J. FIG4 is 
ubiquitously expressed and remove the 5 phosphate of PI(3,5)P2, which is 
enriched in late endosomes and lysosomes (Di Palo and De Camilli, 2006; 
Takatori et al, 2015). 
During my PhD program, we explored the properties and functions of of Fig4 
as wells as its role in the membrane trafficking in order to get insights on the 
molecular mechanism of CMT4J. 
 
Localization and dynamics of Fig4 
The strict control of the subcellular distribution, membrane association and 
activity state of inositol kinases and phosphatases is crucial for the localized 
phosphoinositides signalling and functions.  
We found that Fig4 is localized mainly in the cytoplasm into discrete punctate 
structures that at least partially co-localize with Rab7 indicating that Fig4 is 
enriched/recruited in these compartments. Therefore, they can be the main 
sites where Fig4 acts as supported by the fact that the PIKfyve kinase is also 
enriched in Rab7-compartments (Ikonomov et al, 2006) as well as the 
PI(3,5)P2 (Di Palo and De Camilli, 2006; Takatori et al, 2015). Importantly, 
Fig4 has comparable distribution in neural and in non-neural indicating that it 
undergoes to similar regulation in different cell types.  
In contrast to wild-type protein, we found that both pathological mutants, I41T 
and L17P, displayed a more diffuse intracellular signal suggesting that they 
are unable to be recruited on intracellular compartments. Thus, the punctate 
appearance of Fig4 is connected with its association to intracellular 
membranes and this correlates with the functions of the protein. 
Which is the molecular defect of these mutant proteins? Why they are unable 
to be recruited on intracellular membranes? One possibility is that mutant 
proteins have a fast turn over. Several findings showed that Fig4I41T appears 
to be unstable as consequence of the impairment of its interaction with 
ArPIKfyve, although there are conflicting data (Ikonomov et al, 2010; Lenk et 
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al, 2011). By crystallographic analysis and computational modeling it has 
been shown that the two mutations are surface exposed and located in 
flexible loop regions that may be involved in protein-protein interactions 
(Manford et al, 2010). Thus, mutations could affect putative interactions with 
factors promoting the association and/or stabilization of Fig4 with membranes.  
Overall, these data indicate that the activity of Fig4 is strictly regulated 
through its localization.  
Interestingly, beyond to the cytosolic signal, we found that Fig4 appears also 
distributed in a nuclear structure that resembles the typical nuclear bodies. 
Although at different extent, this distribution is observed in different cell types 
supporting that there is nuclear pool of this enzyme. Some studies suggest 
that the PI(5)P, which is mostly generated from PI(3,5)P2, plays a regulatory 
role in the nucleus through binding ING2 (Gozani et al, 2003; Jones et al, 
2006). Thus, we can postulate that nuclear Fig4 could be implicated in the thin 
regulation of these PIs in the nucleus. It will be interesting to understand 
whether the loss of the putative nuclear function of Fig4 is implicated in the 
CMT4J pathogenesis. We are currently investigating this aspect. 
 
Fig4 regulates the homeostasis of endosomal compartments 
The loss of Fig4 leads to drastic changes in the endo-lysosome system. In 
agreement with observations in plt mice and CMT4J patient fibroblasts (Chow 
et al, 2007; Zhang et al, 2008), we found that in Fig4-silenced cells lysosomes 
are enlarged and more abundant. In addition, also late endosomes appears 
as large dots upon Fig4 silencing. Although this could be expected because 
PI(3,5)P2 is  enriched in these compartments, these data indicate that proper 
concentration of this PI is essential for the homeostasis of these organelles. 
Strikingly, we found that the loss of Fig4 also affects early endosomes as well 
as recycling pathways dependent on them. Instead, no alteration of exocytic 
organelles, endoplasmic reticulum and Golgi apparatus, have been observed, 
indicating that Fig4 is not implicated in the regulation of these membrane 
compartments.  
All these data indicate that the absence of Fig4 affects the homeostasis of 
whole endo-lysosomal axis, highlighting that PI(3,5)P2 plays a key role in the 
endocytic pathway.  
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The lower basal levels found in plt mice (Chow et al, 2007) might impair the 
bulk trafficking of membranes in and out late endosomes with consequent 
enlargements of both later and earlier compartments of endocityc route. In 
yeast, it has been shown that PI(3,5)P2 regulates vacuole fission 
(Bonangelino et al. 2002). On the other hands, always in yeast it has been 
found that the activity of the vacuolar pump V-ATPae, which control the lumen 
acidification and volume, requires the PI(3,5)P2 (Li et al, 2014). Therefore, 
both mechanisms could contribute to the aberrant alteration of endosomal 
compartments.  
Moreover, upon Fig4 loss there is a dysfunction of whole endosomal system. 
Indeed, the trafficking of two receptors (trasnferrin and EGF), which follow 
different fates, is altered in Fig4-depleted cells. For both receptors, we 
observed that there is a protein accumulation inside the cells. In the case of 
transferrin receptor, these results clearly indicate that the recycling pathway is 
impaired, and possibly both the fast (directly from early endosomes) and more 
slowly (passing trough recycling endosomes) route. In the case of EGFR, its 
accumulation may be due to its failure degradation because of dysfunction of 
lysosomes or the impairment of fusion between late endosomes and 
lysosomes, thus preventing to the receptor to reach its final destination. 
Importantly, the activity of Fig4 is crucial for homeostasis and function of 
endocytic compartments in all cells types since we have found the same 
results in different cell lines. 
Thus, all these data indicate that the loss of Fig4 could lead to a dysfunction 
of endosomal compartments and this likely might be the pathogenic 
mechanism in the CMT4J. It is likely that the impairment of the trafficking of 
specific neural proteins (e.g., growth factor and neurotransmitter receptors, 
proteins implicated in neuritogenesis like tag1 etc.) is critical for the 
development of disease. This would explain the sensitivity of different 
neurons. A recent study showing that Fig4-regulated endo-lysosomal 
trafficking is essential for myelin formation in Schwann cells (Vaccari et al, 
2014) supports this hypothesis. Therefore, in the near future it will be 
important to unravel which pathways are altered in neurons. 
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Role of Fig4 in neural differentiation 
We showed that Fig4 is expressed in stem cells and then in differentiated 
cells. Interestingly, in neural cells the Fig4 expression is higher than in 
mesdormal-derived cells, suggesting that Fig4 plays a critical role in the 
nervous system. In addition, while during mesodermal differentiation the 
levels of Fig4 decrease respect to the ESCs and remain stable over time, 
during neural differentiation Fig4 transcripts and proteins follow a peculiar 
kinetic going down and going up at early and late phase of differentiation, 
respectively. These data suggest that for the correct differentiation the Fig4 
levels have to be finely controlled. Consistently, we found that the loss of Fig4 
correlates with altered temporal expression of stemness and early neural 
markers with consequent earlier induction of neural differentiation. This could 
affect the proper development of the nervous system and, therefore, could be 
related with the pathogenesis of the disease.   
 
 
PROJECT 1: MOLECULAR BASIS OF PARKINSON’S DISEASE 
Synj1 was discovered long time ago (McPherson, 1994), while very recently it 
is implicated in a monogenic form of Parkinson (Krebs et al, 2013 Quadri et al, 
2013; Olgiati et al, 2014).  
There is mounting evidence that vesicle trafficking pathways are implicated in 
PD mechanisms since most of the proteins involved in autosomal dominant 
PD as well as those responsible for autosomal recessive form are part, 
directly or indirectly, of the molecular machinery regulating the membrane 
trafficking (Thomas and Beal, 2007; Bonifati et al, 2013).  The knockout mice 
for Synj1 gene die early after birth and have neurological defects such as 
severe weakness, ataxia, spontaneous seizures, poor motor coordination 
(Cremona et al., 1999). The neurons of these mice have impaired the 
endocytic process, although it is not entirely clear the molecular defect. 
To understand the molecular basis of this genetic form of Parkinson we 
analyzed i) its localization in neural and non-neural since the spatiotemporally 
regulation is crucial for this type of enzymes as aforementioned; ii) the effects 
of the silencing of its expression on the regulation of membrane trafficking.  
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In agreement with previous data (Ramjaun and McPherson, 1996; Haffner et 
al, 1997) we found that Synj1 is expressed in different cell types and while in 
neuronal cells is present only the 145 kDa isoform, two isoforms, 145 kDa and 
170 kDa, are expressed at different extent in other cells of different origin. The 
pathological mutation mapped in a common region to the two isoforms, 
therefore this cannot explain the sensitivity of neurons respect to the other 
cells. Although 170 kDA isoform has an additional short PRD domain allowing 
the binding with other proteins (Ramjaun and McPherson 1996; De Heuvel et 
al, 1997; Drouet et al, 2014), it is still unknown if the two isoforms play 
different roles.  
Moreover, we found that both in neural and in non-neural cells Synj1 is 
localized in the cytoplasm mainly along the plasma membrane in agreement 
with the previous findings showing that it interacts with molecules involved in 
the endocytic machinery (such as amphysin, endophilin) and is recruited in 
coated pits (McPherson et al, 1994; McPherson, Takei, et al, 1994; Milosevic 
et al, 2011). In addition, Synj1 is also present in intracellular discrete punctate 
structures more distant from surface, which could be other sites where the 
enzyme acts. Interestingly, in differentiated neuronal cells Synj1 is abundant 
in neurites suggesting that the protein may have a role in neurogenesis and/or 
in preserving neuronal plasticity and, on the other hands, the absence of its 
activity could alter these processes. The fact that Synj1 has been shown 
implicated in synaptic vesicles turn over (MacPherson et al, 1996; Mani et al. 
2007) supports this hypothesis. 
We found that the loss of Synj1 causes a drastic alteration of the early 
endosomes, which result expanded, while does not affect late endosomes. 
Moreover, in absence of Synj1 the trafficking of the transferrin receptor is 
inhibited, but not that to lysosomes of the EGF receptor. Altogether these data 
indicate that the loss of Synj1 causes a dysfunction of the early endosomal 
compartments. On the other hands, these data indicate that Synj1 plays a 
crucial role in regulating the homeostasis and functions of these organelles 
and this role is essential in all cells because we found that the silencing of 
Synj1 expression has similar effects in fibroblasts and neuronal cells. 
Importantly, in patient fibroblasts early endosomal compartments result 
enlarged and the recycling of transferrin is impaired. Thus, these results 
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indicate that the loss of Synj1 as well as the presence of a mutated form of 
the protein (as it occurs in patients) leads to the dysfunction of early 
endosomes. Hence, altogether, these data highlighted that an alteration of 
homeostasis of endosomal compartments might cause the disease. 
While the conversion of PI(4,5)P2 to PI(4) has been shown to be required for 
the removal of clathrin coating and vesicle endocytosis (Cremona et al., 1999; 
Mani et al., 2007), it is likely that phosphatase activity of Synj1 on PIs 
monophosphates (such PI3P and PI4P) may be the cause of the alteration of 
endosomal compartments. Consistently, it has been found that disease-linked 
mutation almost entirely eliminates both the 3- and 4-phosphatse activity, but 
does not affect the activity on PI(4,5)P2  (Krebs et al, 2013).  
Furthermore, we also observed an enlargement of lysosomes in Synj1-
silenced cells. This could be a consequence of the altered membrane 
trafficking from early endosomes. However, the late endosomes are not 
altered as well as the trafficking of EGFR. Otherwise, lysosome alteration 
could be the consequence of the increase of autophagy levels. Our 
preliminary data showed increased levels of autophagy in Synj1 silenced cells 
supporting this hypothesis. Moreover many studies have revealed increased 
autophagy levels in neurodegenerative diseases including Parkinson (Pan et 
al, 2008; Ferguson et al, 2009) supporting this hypothesis. 
 
CONCLUSIONS 
In the last years, an increasing number of human genetic diseases including 
neuropathies have discovered to be associated to mutations in enzymes 
regulating the turnover of PIs, highlighting the central role of these lipids in cell 
homeostasis. 
Our data clearly confirmed that the levels of phosphoinostides might be finely 
regulated and specifically they are critical for membrane homeostasis. Indeed, 
our findings clearly demonstrate that the loss of the activity of two inositol 
phosphatases drastically affects the homeostasis of endo-lysosomal 
compartments, although in different manner. Moreover, our study confirm an 
emerging concept that endosome-lysosome system covers a critical role in 
cellular homeostasis by controlling the degradation of materials from the 
phagocytic, endocytic, autophagic pathways as well as by finely regulating the 
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recycling of proteins back to plasma membrane or their transport toward early 
secretory compartments. In this context, the endosomal PIs play an important 
role.  
Furthermore, our findings indicate that beyond the catalytic activity the 
subcellular distribution and membrane association of phosphatases and 
kinases is critical for metabolism of PI and their functions. 
The proper balance between synthesis and degradation of PIs poses special 
challenges in nervous system that, indeed, appears more sensitive to 
alterations of PI metabolism and, as consequence, to disturbances of 
membrane remodeling and trafficking pathways.  
On this line, our data suggest that the dysfunction of endo-lysosome system 
correlated with the neurodegeneration. 
In conclusion, this study highlighted the cellular defect underlying the 
pathogenesis of CMT4J and Synj1-related PD. Further studies aimed to 
understanding the specific molecular cascades involved (altered in the 
disease) are will necessary and will open the door to the development of new 
therapies. 
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